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PREFACE
Cardiac magnetic resonance (CMR) imaging is now widely 
used in several fields of cardiovascular disease due to 
recent technical developments. For each clinical situation, 
physicians must choose the best imaging modality among 
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echocardiography, cardiac computed tomography (CT), 
CMR or nuclear imaging. However, while each imaging 
modality has individual strengths in specific fields, previous 
studies have just focused on each modality’s feasibility 
and strength separately. Regarding CMR, some guidelines 
for appropriate utilization have been published especially 
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From national databases, 51 articles from the National 
Guideline Clearing House of the United States, 2 from the 
Scottish Intercollegiate Guidelines Network and 16 from 
the National Institute for Health and Care Excellence of 
the United Kingdom were reviewed. In addition, 54 articles 
from PubMed, 40 articles from the Cochrane Library, and 
55 articles from Embase were reviewed. Only publications 
and guidelines from January 2000 to June 2013 were 
selected and reviewed. When guidelines had been revised, 
the most recent version of the guideline was selected for 
review. Guidelines that did not give detailed data on the 
utilization of CMR in relation to overall disease treatment 
or guidelines that were established by expert consensus 
without being supported by objective evidence were 
excluded. Six pre-existing guidelines were finally selected 
for guideline adaptation. To evaluate the quality of pre-
existing guidelines selected for guideline adaptation, 4 
of the Writing Committee members graded each guideline 
according to the Korean Appraisal of Guidelines for Research 
& Evaluation II (K-AGREE II). An evaluation of pre-
existing guidelines was made with the Korean Appraisal of 
Guidelines for Research & Evaluation (K-AGREE) which was 
developed as a Korean version of AGREE 2.0 by the Clinical 
Practice Guideline Executive Committee of the KAMS. Four 
members of the Writing Committee evaluated the 6 selected 
pre-existing guidelines and a reevaluation was done of 
any category with a difference of more than 2 points (1-
7). A standardized score was found for each section and 
compared. Three guidelines that had standardized scores 
for rigour of development category greater than 50% were 
finally chosen. However, these were guidelines for the 
diagnosis and treatment of specific diseases and as such, 
the guidelines for the utilization of CMR were limited to 
those specific medical conditions. Thus, 2 guidelines that 
had high standardized scores were selected additionally 
out of 3 guidelines regarding the indications of CMR. Tables 
for the K-AGREE evaluation results and guideline matrixes 
are given in the Supplement (in the online-only Data 
Supplement). Among the 5 guidelines selected for guideline 
adaptation, some did not present the level of evidence. As 
the level of evidence in some of the guidelines was thought 
to possibly be changed with more recent studies, additional 
papers were searched for each question. PubMed and 
Embase were used to search for supportive evidence and 
the searching parameters were restricted to publications 
between 2000 and 2013, studies done on humans only, and 
studies published in English. After developing appropriate 
in Canada (1) or Europe (2, 3). However, ethnicity, 
socioeconomic status, clinical practice environment, and 
the medical insurance system are different from country 
to country. To overcome ethnic differences, the Asian 
Society of Cardiovascular Imaging (ASCI) published practice 
guidelines for CMR utilization in 2010 (4). Even with this 
effort, differences in socioeconomic status and the medical 
insurance system have still not been fully overcome. In 
addition, more evidence has been collected from when the 
last guideline was published 4 years ago. Therefore, here, 
we have prepared a Korean guideline for the appropriate 
utilization of CMR to guide Korean physicians, imaging 
specialists, medical associates and patients so that the best 
possible practice of CMR is done.
Methods for Establishing the 2014 Korean 
Guidelines for Appropriate Utilization of CMR 
The guidelines presented here were conjointly established 
by the Korean Society of Cardiology (KSC) and the Korean 
Society of Radiology (KSR). The two Societies decided to 
do a guideline adaptation of pre-existing guidelines and 
guideline development was based on the (Adaptation 
Process for Developing Korean Clinical Practice Guidelines) 
published by the Ministry of Health and Welfare in November 
2011. The Clinical Practice Guideline Executive Committee 
of the Korean Academy of Medical Sciences (KAMS) was 
consulted for guideline development methods and a library 
search expert participated during the development of 
the 2014 Korean Guidelines. The Writing Committee was 
comprised of 4 members appointed by the Cardiovascular 
Imaging Research Group of the KSC and 4 members 
appointed by the Korean Society of Cardiovascular Imaging 
of the KSR. The Delphi method was used to develop and 
establish guidelines in consensus. The Rating Committee for 
the Delphi consensus process was comprised of 20 panelists 
who were appointed by the KSR and the KSC. The Writing 
Committee made a first draft of the Korean CMR guidelines 
by consolidating pre-existing guidelines and related 
research study results selected for guideline adaptation and 
the Committee then prepared a questionnaire based on this 
first draft. The final guidelines were established with the 
outcomes found by panels of the Rating Committee through 
three rounds of the Delphi consensus process. For the 
development of the 2014 Korean guidelines, we reviewed 
pre-existing utilization guidelines from US (5), Canada (1), 
Europe (2, 3), and Asia (4), which were written in English. 
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searching formulas for each question, a review was done 
of the search results and evidential studies were selected 
for each related question. When a more recent systematic 
review or a meta-analysis study was found, papers 
previously published with lower levels of evidence were 
excluded along with case reports. Search formulas for each 
category are given in the Supplement (in the online-only 
Data Supplement). 
The levels of evidence given in this guideline are stratified 
into 3 grades and are based on the levels of evidence for 
prognosis and diagnosis published by the Oxford Centre for 
Evidence-Based Medicine in 2011. A level of evidence, of 
either A, B, or C, is provided for each recommendation. The 
following table lists (Tables 1, 2) the levels of evidence and 
how the evidence was graded.
The appropriateness criteria was adapted from the 2010 
American Heart Association cardiac CT appropriateness 
criteria and defined with three ratings: appropriate, 
uncertain, and inappropriate (Table 3). Throughout the 
guidelines, the criteria is marked with A (Appropriate), U 
(Uncertain), or I (Inappropriate) (8).
The questionnaire was based on a first draft of the Korean 
guidelines and had 4 sections with a total of 52 questions. 
A survey was conducted a total of 3 times, and for each 
question, the appropriateness of CMR utilization was graded 
with a response scale; 1–3 points defining the use of CMR 
as inappropriate, 4–6 points as uncertain, and 7–9 points as 
appropriate. When more than 70% of the panelists agreed 
on a grade, the panel was considered to have reached 
consensus for that particular section. The report form for 
the Delphi consensus included appropriateness criteria from 
other guidelines for each category, levels of evidence based 
on searched literature, the response scale (9-point scale), 
sections available for panelists to write in other comments, 
and a reference list for each question. In following 
consensus rounds, questions for which agreement had not 
been reached had both their median score from the previous 
round and the score given in the previous round by the 
answering panelist listed. Response sections of questions for 
which agreement had been reached in previous rounds were 
covered in the questionnaires in the following rounds. No 
modifications were made to questions for which agreement 
had not been reached in the previous round and no other 
comments were written down on the questionnaires by any 
of the panelists. Of a total of 52 questions, a consensus was 
reached on 47 questions in the first survey, 4 questions in 
the second survey, and 1 remaining question on the third 
survey. The response rate for each round was 100%. The 
results of the Delphi voting are included in the Supplement 
(in the online-only Data Supplement).
A total of 10 members, consisting of 1 member of 
the Clinical Practice Guideline Executive Committee of 
the KAMS, 3 of the KSC, 3 of the Korean Pediatric Heart 
Association, and 3 of the KSR, reviewed the guidelines 
selected by consensus, which were later verified at an 
independent audit forum. The development of the current 
Table 1. Definition of Levels of Evidence
Level of Evidence Definition
A Level 1 study, two or more Level 2 studies
B One Level 2 study, two or more Level 3 studies
C One Level 3 study, Level 4 or 5 study
Table 2. Definition of Levels of Study
Level of Study Definition
1 Systematic review, meta-analysis 
2 Individual cross sectional studies with consistently applied reference standard and blinding/Inception cohort studies
3
Non-consecutive studies, or studies without consistently applied reference standards/Cohort study or control arm of  
  randomized trial
4
Case-control studies, or poor or non-independent reference standard/Case-series or case-control studies, or poor  
  quality prognostic cohort study
5 Mechanism-based reasoning
Table 3. Definition of Appropriateness Criteria
Appropriateness Criteria (Score) Definition
A-Appropriate (7–9) Test is generally acceptable and a reasonable approach for the listed indication.
U-Uncertain (4–6)
Test may be generally acceptable and may be a reasonable approach for the indication.  
  Uncertainty also implies that more patient evaluation or patient information is needed to classify  
  the indication definitively.
I-Inappropriate (1–3) Test is not generally acceptable and is not a reasonable approach for the indication.
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guidelines was funded by the KSC and KSR. However, the 
activities of the Writing Committee, the Rating Committee 
for the Delphi consensus and the Reviewing Committee 
that reviewed and verified the selected recommendations 
were independent of one another and none of the three 
Committees were influenced by any of the Societies funding 
the guideline development.
These recommendations should be revised every 3–5 
years, depending on the development of magnetic resonance 
imaging (MRI) technology, changes in the healthcare 
environment, and further accumulation of evidence 
associated with CMR.
Contents
Detection of Coronary Artery Disease (CAD): 
Symptomatic
Clinical Scenario 1: Evaluation of Chest Pain Syndrome
There are several approaches to detect coronary artery 
disease (CAD) using CMR. These include direct visualization 
of coronary arteries using MR coronary angiography, and 
visualization of the effects of induced ischemia using stress 
CMR imaging. Stress CMR imaging can be performed with 
2 different techniques: 1) dynamic first-pass perfusion 
imaging, which assesses inducible perfusion defects, 
indicative of impaired perfusion reserves; and 2) stress-
inducible wall motion abnormalities imaging, which 
evaluates the impairment of regional endocardial excursion 
and myocardial thickening, also indicative of underlying 
ischemia. 
Myocardial Perfusion Imaging 
Cardiac magnetic resonance perfusion imaging is 
performed using a T1-weighted sequence to visualize 
the first passage of a gadolinium based contrast agent 
in transit through the heart. Following the intravenous 
injection, the contrast is detected against a background 
of nulled myocardium with rapid enhancement with and 
without vasodilation stress. Signal intensity correlates with 
contrast concentration, and analysis can be performed in a 
quantitative, semi-quantitative, or qualitative fashion. Visual 
interpretation is usually performed to identify dark areas of 
hypoperfusion relative to normally perfused segments. Semi-
quantification can be performed by measuring the upslope 
of myocardial signal increase (9). Deconvolution analysis 
allowing for the input function from the left ventricular (LV) 
blood pool signal curve can be used to generate regional 
values for the quantitative perfusion index and myocardial 
perfusion reserve (10). 
Validation of CMR perfusion imaging in humans has 
been performed in a number of clinical studies employing 
a variety of contrast agents, analysis techniques, and 
reference standards (11-15). A meta-analysis of CMR 
perfusion studies demonstrated a sensitivity of 91% and 
a specificity of 81% for the diagnosis of CAD with ≥ 50% 
diameter stenosis using catheter-based X-ray coronary 
angiography (XCA) as a reference standard (16). The 
Magnetic Resonance Imaging for Myocardial Perfusion 
Assessment in Coronary Artery Disease Trial (MR-IMPACT) 
study of 241 patients compared the diagnostic performance 
of CMR perfusion imaging and single photon emission 
computed tomography (SPECT) and reported a similar 
overall accuracy (14). In a subsequent larger multicenter 
trial, MR-IMPACT II, of 533 patients, comparing CMR 
perfusion to SPECT suggests a higher sensitivity (75% vs. 
52%, respectively) and lower specificity of CMR perfusion 
(59% vs. 72%, respectively) (15). When the investigators 
performed receiver operator characteristics curve analysis, 
the diagnostic performance estimated as area under the 
curve of CMR perfusion is superior to SPECT (17). However, 
there was a trend towards slightly lower sensitivity and 
specificity in the MR-IMPACT II study compared to the MR-
IMPACT I study (75% vs. 85%, respectively; 59% vs. 67%, 
respectively). This might be related to the larger number 
of sites participating in the MR-IMPACT II study, in which 
less experienced centers might have contributed more to 
the database. Although CMR perfusion is currently thought 
to be an alternative to SPECT to detect perfusion deficit in 
CAD, appropriate physician and staff training and a facility 
capable of performing the stress test are required.
Stress Imaging of Ventricular Function 
Cardiac magnetic resonance can detect myocardial 
ischemia using exercise and pharmacological stressors 
with an accuracy comparable to nuclear imaging and 
echocardiography (18-24). A meta-analysis of stress-
functional CMR studies demonstrated a sensitivity of 83% 
and a specificity of 86% for the demonstration of CAD 
with ≥ 50% diameter stenosis using catheter-based XCA 
(16). Since physical exercise is difficult to perform within 
the magnet bore and often induces motion artifacts, 
pharmacological stress is more commonly used. Dobutamine 
with and without atropine is the most common stressor 
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used for assessment of inducible wall motion abnormalities 
(18-22, 24, 25). Breath-hold gradient echo or steady state 
free precession (SSFP) cines are used to examine regional 
wall function throughout the LV before and during stress 
as the dose of dobutamine is increased in a similar manner 
to dobutamine stress echocardiography. Dobutamine 
stress CMR has a high accuracy for detecting ischemia, 
related in part to excellent LV endocardial visualization 
throughout dobutamine/atropine stress protocols (20). 
Thus, dobutamine CMR appears to be valuable for patients 
who are unsuitable for dobutamine echocardiography (19). 
Dobutamine stress CMR exhibits major complications (i.e., 
the development of sustained ventricular tachycardia) in 
less than 0.1% of subjects, findings that are similar to 
those observed with dobutamine stress echocardiography 
(26).
Other CMR techniques have been used to assess CAD 
with dobutamine. Tagging methods have shown increased 
sensitivity for CAD diagnosis (27). Strain quantification 
using strain-encoded CMR allows early detection of inducible 
ischemia during intermediate stage (28). Real-time CMR 
may be used to monitor wall motion and may eliminate 
the need for breath-holding (24). However, further studies 
are required to determine the clinical role of these imaging 
techniques. 
MR Coronary Angiography
MR coronary angiography is technically more challenging 
than MR angiography of other vascular beds due to 
the small caliber, tortuosity, and complex motion of 
the coronary arteries during the cardiac cycles, and 
the surrounding signal from adjacent epicardial fat and 
myocardium. To overcome these obstacles, several CMR 
approaches are employed. Cardiac triggering (e.g., vector 
electrocardiogram [ECG]) is used to account for intrinsic 
cardiac motion. Although breath-holding can be used to 
suppress respiratory motion, it has limited applicability of 
MR coronary angiography. Navigator echo method can be 
used for respiratory gating and enables free-breathing MR 
coronary angiography. Bright blood technique (segmented 
gradient echo and SSFP) is commonly used without a 
contrast agent, and pre-pulses (e.g., fat saturation, T2 
preparation) are used to enhance the contrast-to-noise 
ratio of the coronary arterial blood. Recently, target-volume 
approach has been largely replaced by the whole-heart MR 
coronary angiography which allows visualization of all major 
coronary arteries with a single axial three-dimensional (3D) 
acquisition in a similar manner to that for CT coronary 
angiography. 
Several studies evaluated the diagnostic performance of 
MR coronary angiography for detecting significant CAD (29-
34). A prospective multicenter, free-breathing, 3D volume-
targeted MR coronary angiography study demonstrated a 
very high sensitivity (100%) and a modestly high specificity 
(85%) with a very high negative predictive value (100%) 
of MR coronary angiography for the identification of left 
main and multi-vessel CAD (29). In a recent prospective 
multicenter study, SSFP whole-heart MR coronary 
angiography demonstrated a high sensitivity (88%) and 
moderate specificity (72%) with a high negative predictive 
value (88%) in the detection of significant CAD (31). 
Clinical utilization of MR coronary angiography has been 
limited for the detection of CAD, mainly due to low spatial 
resolution and long imaging time. However, substantial 
progress in imaging hardware and techniques has been made 
during past decades. The introduction of 32-channel cardiac 
coils permits use of higher parallel imaging acceleration 
factors and substantially reduces the imaging time of MR 
coronary angiography within 10 minutes (35). The higher 
field, 3-T system provides better signal and contrast values 
relative to the 1.5-T system, and thus, may improve the 
detection of CAD with MR coronary angiography (32). A 
recent comparison study of 3-T MR coronary angiography 
with 32-channel cardiac coils and 64-slice CT demonstrated 
similar diagnostic accuracy between the two techniques 
(33). However, to date, data regarding the clinical utility 
of MR coronary angiography for the evaluation of CAD 
are based on high-risk populations referred for catheter-
based XCA. And, importantly, the majority of MR coronary 
angiography data has been generated in only a few highly 
specialized centers. 
CMR for Prognosis Assessment
Prognostic data are now available using both vasodilator 
and dobutamine stress functional CMR methods (36-39). 
In a recent meta-analysis, the annualized event rates for 
composite outcome of cardiovascular death and myocardial 
infarction were 4.9% for positive versus 0.8% for a negative 
stress CMR (39). Another meta-analysis demonstrated a 
high negative predictive value of 98% for cardiac death and 
myocardial infarction of negative stress CMR, and showed 
a similar ability to identify low-risk patients with known or 
suspected CAD (38). In patients with suspected or known 
CAD, stress CMR has excellent prognostic value and may 
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help guide risk stratification. However, data on prognostic 
value of MR coronary angiography is limited. Only a recent 
single study, including 207 patients with suspected CAD, 
reported that significant stenosis detected by MR coronary 
angiography can be used to identify patients at high risk 
for subsequent adverse cardiac events, whereas normal MR 
coronary angiography results are associated with a very low 
event rate (40). 
Detection of CAD: symptomatic
Evaluation of chest pain syndrome (protocols may 
include vasodilator perfusion CMR, dobutamine stress 
function CMR, and/or MR coronary angiography)
1.  Low pre-test probability of CAD/ECG interpretable 
AND able to exercise (Level of evidence: A, 
Appropriateness criteria: I)
2.  Intermediate pre-test probability of CAD/ECG 
interpretable AND able to exercise (Level of evidence: 
A, Appropriateness criteria: U)
3.  Intermediate pre-test probability of CAD/ECG 
interpretable AND able to exercise (Level of evidence: 
A, Appropriateness criteria: A)
4.  High pre-test probability of CAD (Level of evidence: A, 
Appropriateness criteria: U)
Clinical Scenario 2: Evaluation of Coronary Artery 
Anomaly (Use of MR Coronary Angiography) 
Coronary artery anomalies are a diverse group of congenital 
disorders with manifestations and pathophysiological 
mechanisms that are highly variable. Although the 
majority of coronary artery anomalies are not thought to 
be hemodynamically significant, anomalous origination of 
a coronary artery from the opposite sinus with subsequent 
passage between the aorta and pulmonary artery is a well-
recognized cause of myocardial ischemia and sudden cardiac 
death in young individuals (41). Traditionally, catheter-
based XCA has been used to identify these anomalies. 
However, XCA only provides a two-dimensional (2D) view, 
thus the complex 3D course of the anomalous vessel, 
especially in respect to the aorta and pulmonary artery, 
may be difficult to discern. Furthermore, the presence of 
an anomalous vessel is sometimes only suspected even 
after an invasive angiography, because of an unsuccessful 
engagement and visualization of the coronary artery. CT 
coronary angiography and MR coronary angiography are 
alternatives to XCA, which are noninvasive and have the 
multi-planar capability of providing 3D images. MR coronary 
angiography has several significant advantages over XCA 
and CT coronary angiography for diagnosing coronary 
artery anomalies: MR coronary angiography does not 
expose patients to ionizing radiation and can be performed 
without administration of contrast agents at 1.5-T. This is 
an important consideration especially in adolescents and 
younger adults with suspected anomalous CAD. Both 2D 
breath-hold and targeted 3D or free-breathing navigator 
whole-heart MR coronary angiographic methods have been 
used with similar excellent results. However, 3D whole-heart 
MR coronary angiography with a single axial 3D acquisition 
has become the method of choice for MR coronary imaging, 
and is thought to have marked utility relative to the 2D 
projection technique in the assessment of coronary artery 
anomalies (42-47). 
Evaluation of intracardiac structures (use of MR 
coronary angiography)
1.  Evaluation of suspected coronary anomalies (Level of 
evidence: B, Appropriateness criteria: A)
Clinical Scenario 3: Acute Chest Pain 
The use of CMR in the emergency department may allow 
for a more rapid and comprehensive evaluation of patients. 
The unique advantage of CMR imaging is that it can 
provide information on myocardial function, perfusion, and 
infarction in a single scanning session. However, to date, 
there is a paucity of data regarding the utility of CMR in 
the triage of acute chest pain patients. By combining the 
assessment of the left ventricular function, adenosine stress 
perfusion, and late gadolinium enhancement (LGE) imaging, 
CMR demonstrated a sensitivity of 96% and a specificity of 
83% for the detection of significant stenosis in 68 patients 
with non-ST-segment elevation myocardial infarction (48). 
Otherwise, there have only been 2 small single-center 
observational trials in patients with acute chest pain and 
an inconclusive evaluation in the emergency department. 
CMR including the LV function, resting perfusion, and LGE 
imaging was performed in 161 patients with acute chest 
pain and showed a sensitivity of 84% and a specificity of 
85%, respectively (49). In a smaller study with 62 patients, 
the addition of the T2-weighted sequence for the detection 
of myocardial edema improved the specificity and positive 
predictive value for acute coronary syndrome to 96% and 
85% (50). Management of intermediate-risk patients with 
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possible acute coronary syndrome in an observational unit 
with CMR may reduce medical costs during the index visit 
and subsequent to discharge over the first year (51). The 
reduction in costs even after discharge is thought to be 
associated with fewer coronary artery revascularizations, 
fewer hospital readmissions, and fewer cases of recurrent 
cardiac testing (52). However, as with the diagnostic 
accuracy literature for CMR, studies in this area are 
primarily single-center reports that describe the findings 
of experienced observers in a small number of patients. 
Thus, at present, the level of evidence is low, and larger 
multicenter investigations should further build on these 
results.
Acute chest pain (protocols may include vasodilator 
perfusion CMR or dobutamine stress function CMR)
1.  Low pre-test probability of CAD/No ECG changes and 
serial cardiac enzyme negative (Level of evidence: A, 
Appropriateness criteria: U)
2.  Intermediate pre-test probability of CAD/No ECG 
changes and serial cardiac enzyme negative (Level of 
evidence: A, Appropriateness criteria: U)
3.  High pre-test probability of CAD/No ECG changes and 
serial cardiac enzyme negative (Level of evidence: A, 
Appropriateness criteria: U)
4.  High pre-test probability of CAD/ECG–ST-segment 
elevation and/or positive cardiac enzymes (Level of 
evidence: A, Appropriateness criteria: I)
Clinical Scenario 4: Detection of CAD with Prior Test 
Results 
An important decision facing clinicians is whether 
a noninvasive cardiac imaging result warrants 
revascularization or whether medical management is most 
appropriate. Current guidelines recommend proof of ischemia 
prior to elective revascularization (53-55). However, the 
severity of coronary stenosis assessed by catheter-based 
XCA or CT coronary angiography does not correlate well 
with functional significance assessed by the fractional flow 
reserve (FFR) (56). The relevance of this discrepancy has 
been highlighted by results of the Fractional Flow Reserve 
versus Angiography for Multivessel Evaluation (FAME) trial, 
which demonstrated improved cardiac outcome when FFR 
measurements were taken during coronary intervention 
for multi-vessel disease (57, 58). These results show the 
importance of assessing the functional significance of CAD 
in addition to anatomic evaluation, supporting the use of 
noninvasive testing for guiding revascularization. 
Stress CMR, either with vasodilator or dobutamine stress, 
has been shown to have high diagnostic accuracy for the 
detection of significant CAD (13-16, 59). Several studies 
have compared stress CMR perfusion imaging with the 
invasive reference standard, FFR, and have demonstrated 
good correlation between stress CMR perfusion imaging 
and FFR (60-63). In a single center study by Watkins et al. 
(62), 103 patients with suspected angina underwent stress 
CMR perfusion imaging and catheter-based XCA and FFR was 
measured in all major patent epicardial coronary arteries. 
Stress CMR perfusion imaging can detect functionally 
significant CAD defined as FFR < 0.75 with excellent 
sensitivity (91%), specificity (94%), and positive and 
negative predictive values (91% and 94%, respectively). 
In a recent study by Groothuis et al. (64), the addition of 
stress CMR perfusion imaging to CT coronary angiography 
significantly improved specificity and overall diagnostic 
accuracy for the detection of significant CAD as defined 
by catheter-based XCA with conditional FFR measurement. 
Thus, in clinical practice, stress CMR can subsequently be 
used to assess the hemodynamic significance of CAD and to 
direct revascularization. 
Stress CMR provides excellent prognostic stratification of 
patients with known or suspected CAD with a high negative 
predictive value for adverse cardiac events (38, 39). Further, 
it has a number of advantages over the other noninvasive 
techniques, including high spatial and temporal resolution, 
no exposure to ionizing radiation, no attenuation or scatter 
artifacts, and no image orientation constraints. However, it 
is currently difficult to conclude that using ischemic burden 
to guide the decision for revascularization with stress CMR 
is superior compared to other noninvasive tests. Although 
a few previous studies have reported a higher diagnostic 
accuracy of stress CMR in comparison to myocardial SPECT, 
the majority of studies have compared diagnostic accuracy 
for the detection of significant CAD, using catheter-based 
XCA as the reference standard (13-15, 17, 65). It needs to 
be confirmed whether stress CMR guided revascularization 
truly achieves a therapeutic reduction in ischemia or truly 
improves outcomes. 
Combining stress perfusion and wall motion assessment 
with LGE and/or coronary artery anatomy may further 
increase the diagnostic and prognostic power of stress 
CMR. In a large prospective study entitled Cardiovascular 
Magnetic Resonance and Single-photon Emission Computed 
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Tomography for Diagnosis of Coronary Heart Disease (CE-
MARC), multiparametric CMR including LV function, stress 
perfusion, LGE, and MR coronary angiography, demonstrated 
superior diagnostic accuracy compared to SPECT (13). 
However, further studies are necessary to determine whether 
LGE or MR coronary angiography provides incremental 
information to stress CMR in the decision making process 
for revascularization. 
Detection of CAD: with prior test results (protocols 
may include vasodilator perfusion CMR or dobutamine 
stress function CMR)
1.  Normal prior stress test (exercise, nuclear, echo, 
MRI)/high CHD risk (Framingham)/within 1 
year of prior stress test (Level of evidence: A, 
Appropriateness criteria: I)
2.  Equivocal stress test (exercise, stress SPECT, or stress 
echo)/intermediate CHD risk (Framingham) (Level of 
evidence: A, Appropriateness criteria: U)
3.  Coronary angiography (catheterization or CT)/
stenosis of unclear significance (Level of evidence: C, 
Appropriateness criteria: A)
Clinical Scenario 5: Evaluation of CAD in Patients 
with Post Percutaneous Coronary Intervention (PCI) or 
Coronary Artery Bypass Grafting (CABG)
Several studies had reported that 10% of postoperative 
grafts had been occluded either during or immediately 
after coronary artery bypass grafting (CABG). Moreover, in 
a 10 year follow-up study after the surgery, 59% of vein 
grafts and 17% of artery grafts had been occluded (66-
68). Therefore, reliable diagnostic methods for patency 
assessment are needed after CABG. Cardiac CT and CMR are 
noninvasive methods geared toward this end. Some studies 
have shown that high-resolution MR angiography provides 
fair diagnostic accuracy in evaluating the severity of vein 
graft stenosis comparing with invasive coronary angiography 
in patients with recurrent chest pain or in asymptomatic 
patients after bypass surgery (69, 70). However, until now, 
most studies used cardiac CT to assess graft vessel patency 
after CABG and only a small number of studies utilized CMR 
for this purpose. Therefore, further studies on CMR in this 
capacity are warranted.
Regular clinical evaluation of stent restenosis is 
recommended in patients who have undergone percutaneous 
coronary intervention (PCI) with stent placement (55). 
Although several studies had suggested that CMR imaging 
of coronary stents is a safe and promising non-invasive 
method that assessing patency of the coronary stents 
(71-73), the use of MR coronary angiography for this 
purpose is limited by low-signal artifacts that occur at the 
stenting site and direct evaluation of in-stent restenosis 
is not possible. Therefore, MR coronary angiography is not 
recommended as an appropriate method for the routine 
evaluation of in-stent restenosis. Also, the indirect 
approach of inferring the degree of stenosis through the 
presence of distal flow turbulence has been known to have 
little credibility (74, 75).
Evaluation of CAD: post PCI or CABG
Evaluation of chest pain syndrome (use of MR coronary 
angiography)
1.  Evaluation of bypass grafts (Level of evidence: C, 
Appropriateness criteria: U)
2.  History of percutaneous revascularization with stents 
(Level of evidence: C, Appropriateness criteria: I)
Asymptomatic (use of MR coronary angiography)
1.  Evaluation of bypass grafts and coronary anatomy 
(Level of evidence: C, Appropriateness criteria: I)
2.  Evaluation for in-stent restenosis and coronary 
anatomy after PCI (Level of evidence: C, 
Appropriateness criteria: I)
Clinical Scenario 6: CAD Risk Assessment: Preoperative 
Evaluation 
The decision to conduct a preoperative cardiac evaluation 
is made based on the surgery-specific cardiac risk and 
patients scheduled for low-risk surgery can proceed to 
the surgery without further testing. However, when an 
intermediate- to high-risk surgery is scheduled, for which 
the risk of a myocardial infarction or cardiac mortality is 
around 5%, additional cardiac evaluation may be necessary 
(76-80). Additional heart tests are required when three 
or more clinical risk factors are present or when patient’s 
functional capacity is poor. Because there is an increased 
risk associated with surgery, a noninvasive cardiac stress 
test is recommended before surgery (76, 77, 81).
As a noninvasive preoperative cardiac testing method, 
CMR has the advantages of providing superior spatial 
and temporal resolution without exposure to harmful 
radiation in contrast to cardiac CT or myocardial perfusion 
scintigraphy, and of having more precision in cardiac 
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evaluation than echocardiography in case with a poor 
acoustic window. Therefore, CMR has recently been used 
more frequently in clinical practice as a preoperative 
test for myocardial viability and perfusion, valvular heart 
disease, cardiomyopathy, and congenital heart disease 
(82). In particular, in patients who showed a negative 
stress perfusion CMR examination, the probability of 
not experiencing cardiac death or a nonfatal myocardial 
infarction for at least 3 years is as high as 99.2%, 
indicating a very low likelihood of future cardiovascular 
disease (37). Additionally, in meta-analysis of 21 studies 
that observed a total of 1233 subjects, stress perfusion CMR 
examination scored high on its ability to assess obstructive 
CAD with a sensitivity of 84% (range, 44–93%) and a 
specificity of 80% (range, 60–100%); therefore, CMR is 
thought to be very useful in the preoperative assessment of 
CAD (37, 83). Furthermore, CMR is known for its excellence 
in assessing the LV ejection fraction and LV volume, which 
predicts the occurrence of postoperative heart failure. 
However, a disadvantage that must be mentioned is the 
difficulty of performing a CMR examination in patients with 
an artificial pacemaker, implantable defibrillator, or insulin 
pump. Thus, the patient’s condition should be taken into 
account when performing CMR.
CAD risk assessment: preoperative evaluation 
(protocols may include vasodilator perfusion CMR or 
dobutamine stress function CMR)
1.  Low-risk non-cardiac surgery in patients with 
intermediate perioperative risk predictors (Level of 
evidence: C, Appropriateness criteria: I)
2.  Intermediate or high risk non-cardiac surgery 
in patients with intermediate perioperative risk 
predictors (Level of evidence: C, Appropriateness 
criteria: U)
3.  CAD evaluation before valve surgery (Level of 
evidence: C, Appropriateness criteria: U)
Clinical Scenario 7: Evaluation of CAD: in Pediatric 
Patients with Kawasaki Disease
Echocardiography is the bedside technique of choice 
during the acute phase of the disease. CMR can be a 
valuable tool especially in children and adolescents, where 
sometimes echocardiography fails to detect coronary 
abnormalities and it has also the advantage of simultaneous 
perfusion, function and viability evaluation. If CMR is not 
available, a combination of echocardiography and SPECT 
gives an overview of anatomy, function and perfusion. 
Cardiac CT is of limited value for follow-up because 
of radiation and the misleading data due to coronary 
calcifications. Catheter-based XCA is kept mainly for cases 
where an invasive procedure should be performed (84). 
Mavrogeni et al. (85, 86) compared the results of MR 
coronary angiography with XCA in a pediatric population 
(87). In the 6 patients, aneurysms of the coronary arteries 
were identified, while coronary ectasia alone was present 
in the remaining seven patients. MR coronary angiography 
and XCA diagnosis of coronary artery aneurysm (CAA) 
agreed completely. Maximal aneurysm diameter and length 
and ectasia diameter by MRA and XCA were similar. No 
stenotic lesion was identified by either technique. Another 
prospective study compared MR coronary angiography and 
XCA findings in patients with CAAs. There was complete 
agreement between MR coronary angiography and XCA in 
the detection of CAA (n = 11), coronary artery stenoses (n 
= 2), and coronary occlusions (n = 2). Excellent agreement 
was found between the 2 techniques for detection of CAA 
maximal diameter (mean difference = 0.4 ± 0.6 mm) and 
length (mean difference = 1.4 ± 1.6 mm). The 2 methods 
showed very similar results for proximal coronary artery 
diameter and CAA distance from the ostia (88).
Evaluation of CAD: in pediatric patients with 
Kawasaki disease (use of MR coronary angiography)
Asymptomatic
1.  No previous definitive test (catheterbased XCA, MR 
coronary angiography, or CT coronary angiography) 
available (Level of evidence: B, Appropriateness 
criteria: U)
2.  Previous tests (catheter-based XCA, MR coronary 
angiography, or CT coronary angiography) 
documented coronary aneurysm/stenosis, for follow-
up (Level of evidence: B, Appropriateness criteria: A)
Symptomatic
1.  No previous definitive test (catheterbased XCA, MR 
coronary angiography, or CT coronary angiography) 
available (Level of evidence: B, Appropriateness 
criteria: A)
2.  Previous tests (catheter-based XCA, MR coronary 
angiography, or CT coronary angiography) 
documented coronary aneurysm/stenosis, for follow-
up (Level of evidence: B, Appropriateness criteria: A)
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Clinical Scenario 8: Detection of CAD: Asymptomatic
Regarding role of CMR for detecting occult CAD, no 
well controlled studies have been reported. Especially, no 
efficacy data have been reported regarding “screening” MR 
coronary angiography in high-risk populations. Although 
other imaging modalities such as coronary calcium scoring 
has some evidences for risk stratifications in asymptomatic 
populations, CMR based stress perfusion study or MR 
coronary angiography based CAD detection need evidence 
to get any appropriateness levels. Therefore in this category 
of patients, performing CMR is not generally recommended 
in low- or intermediate-risk populations. Regarding in high 
risk asymptomatic populations, experts’ recommendations 
from ASCI provide uncertain level with scoring 6, which 
means it may be a “reasonable approach” (4, 89).
Detection of CAD: asymptomatic (protocols may 
include vasodilator perfusion CMR, dobutamine stress 
function CMR, and/or MR coronary angiography)
1.  Low CHD risk (Framingham) (Level of evidence: A, 
Appropriateness criteria: I)
2.  Moderate CHD risk (Framingham) (Level of evidence: 
A, Appropriateness criteria: U)
3.  High CHD risk (Framingham) (Level of evidence: A, 
Appropriateness criteria: U)
Clinical Scenario 9: Detection of Myocardial Scar and 
Viability in Ischemic Heart Disease
In patients with ischemic heart disease, discrimination 
of unviable necrotic areas from a viable area such as a 
stunned myocardium is important in the prediction of the 
potential recoverability of myocardial contractility and 
in the planning of future treatment directions. Contrast-
enhanced CMR that uses gadolinium has been reported 
to be useful in the evaluation of myocardial viability 
by many studies. Contrast-enhanced CMR can also be 
performed on myocardial infarction patients before coronary 
artery revascularization to predict the post-procedural 
reversibility of myocardial contractility (90, 91). A recent 
meta-analysis that evaluated the ability of LGE CMR to 
discern stunned myocardium that may be reversible in 
patients with myocardial infarction scheduled for coronary 
revascularization reported sensitivity of 87%, a specificity 
of 68%, a positive predictive value of 83%, and a negative 
predictive value of 72%, for an overall diagnostic accuracy 
of 82% in those surveyed. The dobutamine stress CMR 
technique was also evaluated and was found a sensitivity 
of 67%, a specificity of 81%, a positive predictive value of 
82%, a negative predictive value of 63%, and an overall 
diagnostic accuracy of 74%. Therefore, CMR was founded 
to be useful in the evaluation of myocardial viability (92). 
Furthermore, in a meta-analysis of 4438 CAD patients, when 
the CMR examination detected LGE lesions, patients had 
a 2.65 (95% confidence interval [CI], 1.98–3.56) greater 
risk of developing major cardiovascular events (MACE), 
and a relationship to the size of the LGE in the lesion 
was found with every 10% of the LV affected leading to a 
56% (95% CI, 1.39–1.75) increase in MACE development. 
These reports support the useful prognostic value of CMR in 
predicting MACE in patients with prior myocardial infarction 
(93). Thus, based on reports of its usefulness in patients 
scheduled for coronary revascularization, CMR has become 
a recognized pre-procedural assessment method of the 
viability of cardiac function recovery.
Many studies have reported that dobutamine stress CMR 
and LGE CMR are important in the evaluation of myocardial 
viability. In particular, Romero et al. (94) reported in a 
meta-analysis of 24 studies including 698 patients, that LGE 
CMR scored high with a sensitivity and negative predictive 
value of 95% and 90%, respectively, and that dobutamine 
stress CMR scored 91% and 93% on specificity and positive 
predictive value, respectively. They therefore concluded 
that a more accurate prediction of cardiac function after 
coronary revascularization can be achieved by analyzing the 
results of several studies (94-96).
Late gadolinium enhancement CMR was also compared 
to other noninvasive tests for myocardial viability, such as 
dobutamine stress echocardiography and SPECT. First, when 
comparing SPECT to CMR, while there was no significant 
difference in each method’s ability to detect myocardial 
transmural necrosis or normal myocardium, LGE CMR was 
superior to SPECT in the detection of subendocardial 
infarction owing to its superior spatial resolution (97-99). 
In addition, a recent prospective study has shown that 
CMR has a sensitivity of 86.5% and a specificity of 83.4% 
in the detection of CAD, which are superior to the 66.5% 
sensitivity and 82.6% specificity reported for SPECT (13). 
Likewise, CMR appears to be superior to dobutamine stress 
echocardiography, which is known to have a similar overall 
accuracy to that of SPECT on the basis of a meta-analysis 
that compiled 11 studies and reported a sensitivity of 
79% and specificity of 87% (100). Taken together, these 
results indicate that stress CMR has a special significance 
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for patients who tested negative for low to moderate risk 
of CAD and for patients who tested positive for a high risk 
of CAD. CMR has therefore been shown to be effective for 
patients who tested as being moderately at risk by other 
noninvasive examination methods (16).
As previously described, it is known that LGE CMR is a 
good method for evaluating the size of myocardial necrosis 
prior to coronary revascularization and for determining 
whether or not myocardial necrosis after coronary 
revascularization is likely to occur and to what extent. 
When observing patients scheduled for PCI, an increase 
in post-procedural troponin I level has been reported 
to show a strong positive correlation to the area of new 
myocardial enhancement as detected by LGE CMR. Moreover, 
in patients with an elevated level of creatinine kinase-MB, 
which indicates necrosis of the myocardium, LGE could be 
observed in structurally associated parts, indicating that 
it is possible to check for incidence of immediate post-
procedural myocardial infarction (101). Based on their 
research studies on acute ST elevated myocardial infarction 
patients, Eitel et al. (101, 102) concluded that the 
myocardial salvage index measured by CMR is related to the 
incidence of long-term MACE such as cardiac death and that 
it is therefore an important independent prognostic factor.
Thus, it is believed that the implementation of CMR after 
coronary revascularization procedures can help assess the 
incidence of myocardial injury and that CMR can find further 
application as an indicator of patient prognosis (103).
Detection of myocardial scar and viability (protocols 
may include LGE evaluation or dobutamine stress 
function CMR)
1.  To determine the location and extent of myocardial 
necrosis including ‘no reflow’ regions/post-
acute myocardial infarction (Level of evidence: A, 
Appropriateness criteria: A)
2.  To detect post PCI myocardial necrosis (Level of 
evidence: A, Appropriateness criteria: A)
3.  To determine viability prior to revascularization/
establish likelihood of recovery of function with 
revascularization (PCI or CABG) or medical therapy 
(Level of evidence: A, Appropriateness criteria: A)
4.  To determine viability prior to revascularization/
viability assessment by SPECT or dobutamine echo 
has provided “equivocal or indeterminate” results 
(Level of evidence: A, Appropriateness criteria: A)
Structure and Myocardial Functional Evaluation in 
Patients with Risk of Heart Failure or Overt Heart Failure
Clinical Scenario 10: Evaluation in Patients with Risk of 
Heart Failure or Overt Heart Failure (General)
The main symptoms of heart failure include shortness of 
breath, fatigue, and exercise intolerance, resulting from 
variable combinations of fluid retention in the body and 
significant decline in tissue perfusion (104). Physical 
examination in heart failure patients can reveal cardiac 
murmur, jugular venous engorgement, pedal edema, 
crackles, and/or cold extremities, depending on the heart 
failure severity (104). Heart failure is characterized by an 
abnormality of cardiac structure and/or function, leading 
to the impairment of the heart ability to meet the oxygen 
requirements of the tissues (104). Therefore, any cardiac 
diseases at the terminal stages can clinically cause heart 
failure. Although the definition of heart failure seems to be 
straightforward, its diagnosis is not always easy to make. 
Many heart failure symptoms are nonspecific or even vague 
and therefore, of limited diagnostic value (105, 106). 
Heart failure can be caused by the abnormal function of 
the myocardium, valves, and/or pericardium and even their 
combinations, but the exact etiology cannot be clearly 
differentiated with only history taking and/or physical 
examination (105, 106). Also, the majority of heart failure 
patients become symptomatic with the development of 
myocardial dysfunction, which can be observed with a 
diverse spectrum of clinical states. Myocardial dysfunction 
can range from severely decreased ventricular systolic 
dysfunction with or without ventricular dilation to preserved 
ventricular systolic function (as assessed by ejection 
fraction) with normal ventricular size, both of which are 2 
important types of heart failure, that is heart failure with 
reduced ejection fraction and heart failure with preserved 
ejection fraction, respectively (104). Thus, assessment of 
the systolic as well as the diastolic function of the ventricle 
plays a central role in the diagnostic process of heart 
failure. Echocardiography is a well-known and established 
technique for assessing anatomical structure and function 
(systolic and diastolic) of the ventricle and this is one of 
the important reasons why echocardiography has taken a 
main position in the evaluation of heart failure. In fact, 
echocardiography has been widely employed to assess 
changes in ventricular size or volume, shape and function 
in many clinical trials (107-111). In this respect, there is 
no doubt that echocardiography is the first-line imaging 
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modality for the evaluation of heart failure patients. 
Nevertheless, echocardiography suffers from a wide inter-
observer variation in measurements of size and function, 
and furthermore, is vulnerable to image quality that is 
variable from patient to patient (108). In comparison, the 
image quality of CMR is not a main concern for analysis, and 
due to its inherent characteristics, post-processing does not 
require any geometric assumptions for ventricular volume 
quantification (112). This is of particular importance in 
the evaluation of heart failure patients, given that many 
heart failure patients experience geometric changes in their 
ventricles with a large regional variation in contractility, 
which can predispose to errors in measurements of volume 
and ejection fraction by echocardiography. In addition, due 
to its high accuracy and reproducibility, CMR is believed 
to be the best reference standard imaging modality for 
the noninvasive, in vivo assessment of ventricular volume, 
mass, and function (112-116). CMR also allows for accurate, 
serial, longitudinal assessment of changes in ventricular 
size and function after therapeutic interventions on an 
individual patient basis. Therefore, sample sizes for any 
study can be far reduced with the use of CMR rather 
than echocardiography in the longitudinal assessment of 
ventricular volumes, mass and function (117). 
Identification of heart failure etiology should be a 
fundamental question addressed before a final decision 
is reached on therapeutic plans. Although structure and 
function are the two main targets for heart failure imaging, 
CMR can provide clues to underling abnormalities leading 
to heart failure (118, 119). CMR is highly accurate and 
reproducible in ventricular volume and ejection fraction 
measurements, as commented above. On top of that, 
myocardial perfusion, viability, and fibrosis imaging 
(using the LGE technique) by CMR can help identify heart 
failure etiology and predict prognosis (119, 120). In 
addition, LV mass quantification by CMR predicts prognosis 
in heart failure patients (121, 122). Among a variety 
of CMR techniques, LGE CMR provides a non-invasive 
imaging approach to determine the underlying etiology 
of heart failure by allowing for a direct interrogation of 
the myopathic process (118). Differentiation between 
ischemic and non-ischemic etiology is a basic step for 
heart failure assessment because this classification exerts 
a significant effect on patient management decision 
and patient prognosis (123). LGE CMR can help, in many 
cases, differentiation of the 2 conditions based on the LGE 
pattern. Ischemic LGE pattern is characterized by a 100% 
involvement of the subendocardium, i.e., subendocardial 
or transmural, and should be found in a region consistent 
with a perfusion territory of an epicardial coronary artery 
(124). In contrast, a non-ischemic LGE pattern usually 
spares the subendocardium, i.e., mid-wall or epicardial, 
and/or is inconsistent with a perfusion territory subtended 
by one coronary artery (124). LGE CMR is also helpful 
for the diagnosis of any specific type of non-ischemic 
cardiomyopathy causing heart failure, which can be finally 
achieved by analyzing the location and pattern of LGE. For 
example, asymmetric septal hypertrophic cardiomyopathy 
(HCM) is characterized by LGE of both junctions of the right 
ventricular (RV) and interventricular septum in the mid-
wall (125), whereas apical LGE is frequently found in apical 
HCM (126). Mid-wall and epicardial LGE in the inferolateral 
segments can be found in patients with Anderson-Fabry 
disease (127), whereas LGE found in cardiac sarcoidosis 
can be variable. But subepicardial or midwall involvement, 
especially in basal septum, is unique findings of cardiac 
sarcoidosis (25). Cardiac amyloidosis has a typical LGE 
pattern, i.e., subendocardial, diffuse ring enhancement, 
with difficulty in determining optimal inversion time 
to null normal myocardium due to of its characteristic 
diffuse myocardial involvement (128). Myocarditis can be 
diagnosed with LGE CMR and T2 edema imaging (129, 130). 
Assessment of transmurality of LGE is a good surrogate 
marker for prognosis prediction (129). Combined CMR 
assessment of LGE extent and CMR-based LV ejection 
fraction is reported to be of prognostic value in heart 
failure patients (131). 
Approximately 50% of deaths in heart failure patients 
occur suddenly and unexpectedly. Thus, prevention of these 
unexpected events is another important target for heart 
failure management. Implantable cardioverter-defibrillator 
(ICD) therapy is a life-saving strategy in heart failure 
patients with severely decreased LV ejection fraction. 
Recent studies showed that assessment of myocardial 
scarring by LGE CMR can improve risk stratification in heart 
failure patients who are considered potential candidates for 
ICD therapy (132, 133). Gao et al. (134) also demonstrated 
that assessment of the total scar by LGE CMR can predict 
an arrhythmic event. Despite no CMR criteria suggested by 
the heart failure guideline published in 2012 (104), CMR-
based ICD therapy seems to hold promise in the prediction 
of patients who may benefit from ICD therapy. The same 
strategy can be true for determining potential candidates 
of cardiac resynchronization therapy (CRT) or for planning 
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CRT procedures (135-137), but this has yet to be confirmed 
with more data.
Although some case series have reported the safety and 
effectiveness of the CMR-based approach in heart failure 
patients with ICD (138, 139), this is not generally accepted 
in the current era, and great care should be exercised before 
it is adopted into daily clinical practice. Generally, CMR is 
not recommended in patients with ICD or CRT devices.
Evaluation in patients with risk of heart failure 
or overt heart failure (general) (protocols may 
include LV/RV mass and volumes, MR angiography, 
quantification of valvular disease, and LGE 
evaluation)
1.  Evaluation of LV function following myocardial 
infarction OR in heart failure patients (Level of 
evidence: A, Appropriateness criteria: A)
2.  Evaluation of LV function following myocardial 
infarction OR in heart failure patients/patients with 
technically limited images from echocardiogram 
(Level of evidence: A, Appropriateness criteria: A)
3.  Quantification of LV function/discordant information 
that is clinically significant from prior tests (Level of 
evidence: A, Appropriateness criteria: A)
4.  Evaluation in patients with new onset heart failure to 
assess etiology (Level of evidence: A, Appropriateness 
criteria: A)
5.  Initial evaluation of structure and function for newly 
suspected or potential heart failure (also including 
malignancy on current or planned cardiotoxic 
therapy, survived patients with suspected ventricular 
dysfunction after chemotherapy, and no prior imaging 
evaluation/familial or genetic cardiomyopathy in 
first-degree relative, known congenital heart disease 
with suspected ventricular dysfunction, acute 
myocardial infarction during initial hospitalization) 
(Level of evidence: A, Appropriateness criteria: A)
6.  Evaluation to determine patient candidacy of ICD 
therapy (ejection fraction and/or other structural 
information) (Level of evidence: A, Appropriateness 
criteria: A)
7.  Initial evaluation to determine patient candidacy 
of CRT or procedural planning (ejection fraction, 
fibrosis, scarring, coronary vein variation, and 
intracavitary thrombus) (Level of evidence: A, 
Appropriateness criteria: A)
8.  Cardiac function follow-up after ICD or CRT (Level of  
evidence: C, Appropriateness criteria: I)
Clinical Scenario 11: Patients with Congenital Heart 
Disease
Cardiac magnetic resonance is very useful in the 
evaluation of congenital heart disease because complete 
contiguous data sets from cardiac base to apex can give 
complete descriptions of cardiac and extra-cardiac anatomy 
of both simple and complex congenital heart disease 
very effectively. Unlike cardiac CT, ionizing radiation 
exposure is not an issue for CMR, allowing for repeated or 
sequential evaluation of children and young adults without 
radiation concern. Nevertheless, CMR is limited in critically-
ill patients, especially in acute settings or in patients 
who cannot cooperate with the medical team, especially 
neonates and infants. Therefore, CMR is in most cases used 
as an adjunct approach to echocardiography. Thus, review 
of echocardiographic images can aid in the appropriate 
selection of CMR sequences that are likely to give answers 
to unresolved questions. Although CMR is less operator-
dependent when compared to echocardiography, a thorough 
understanding of the anatomical and functional aspects of 
any given congenital heart disease is absolutely necessary 
for a complete interrogation of that particular congenital 
heart disease patient. A comprehensive evaluation of 
cardiac and extra-cardiac anatomic structures can be imaged 
as well, which makes CMR clinically useful in complex 
congenital heart disease patients. 
Anomalies of Coronary Circulation 
Although CT coronary angiography offers much clearer 
anatomical information, the origin and proximal course of 
the coronary arteries can still be relatively well investigated 
by MR coronary angiography (45). For patients who have 
difficulty in holding their breath, real-time coronary 
imaging using diaphragm navigators can be used to 
minimize image blurring (42). MR coronary angiography is 
also useful in the identification of inflammatory changes in 
the coronary artery, such as changes that would occur with 
Kawasaki disease (87).
Anomalies of Great Vessels (Anomalies of Aorta and 
Pulmonary Artery)
MR angiography is also very effective for a complete 
evaluation of the great vessels. Coarctation of the aorta is 
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one representative disease. Transthoracic echocardiography 
using the 2D and Doppler technique is in many cases 
enough to diagnose and evaluate hemodynamic severity, 
but some difficulties can be encountered. Under these 
situations, CMR can provide diverse and extensive 
information regarding the severity and extent of stenosis, 
collateral circulation, and morphologic changes in the 
ascending aorta, and associated anomalies in the aortic 
valve. CMR is also a good imaging modality after surgical 
correction or angioplasty (140-142). Contrast-enhanced 3D 
MR angiography can show abnormal sources of pulmonary 
blood supply from the major aorta associated with 
pulmonary stenosis or atresia, though CT angiography is 
more sensitive at detecting small vessels connected to the 
pulmonary vessels (143, 144).
Due to the ability of CMR to reliably assess the entire 
aorta and its major branches, aortic disease accompanied 
by systemic diseases like Marfan syndrome or Ehler-Danlos 
syndrome can be accurately investigated. In addition, 
CMR can detect in the preclinical stage abnormal aortic 
elastic properties in affected patients before aortic dilation 
clinically manifests (145, 146). 
Assessment of Cardiac Chambers and Valves
Cardiac magnetic resonance is an excellent technique 
for defining the morphologic features of ventricles 
(147). Thus, it is easy to determine which ventricle the 
morphological RV is and which ventricle the morphological 
LV is with comprehensive CMR assessment. For this purpose, 
detailed knowledge of the LV and RV is a prerequisite; 
the morphological RV is characterized by multiple coarse 
trabeculations including the moderator band, and is always 
connected to the tricuspid valve that is located more 
apically without exception in relation to the mitral valve. 
Thus, complex congenital heart disease like transposition 
of the great arteries or congenitally corrected transposition 
of the great arteries can be accurately assessed (148, 
149). In addition, CMR is also very valuable in terms of 
postoperative follow-up of these patients (149, 150). CMR 
can easily detect the presence of an intra-cardiac shunt like 
a ventricular septal defect (VSD) or atrial septal defect (ASD) 
with jets localization and shunt quantification (151-154). 
It is in no doubt that echocardiography is the first line 
of investigation for patients with valve diseases including 
congenital valve lesions (155). However, CMR can provide 
additional information to that offered by echocardiography, 
especially in patients with poor echocardiographic windows 
and patients with right-sided valve diseases. Thanks 
to its high spatial resolution and signal-to-noise ratio, 
morphologic or pathological changes in cardiac valves of 
interest can be assessed. In addition, phase contrast imaging 
allows for the accurate quantification of regurgitant volume. 
This can be specifically applied to patients with significant 
pulmonary regurgitation. The ability of CMR to quantitate 
regurgitant volume is particularly valuable for the sequential 
monitoring of pulmonary regurgitation severity in patients 
with tetralogy of Fallot who have undergone RV outflow 
tract patch surgery (156, 157). Sequential evaluation of 
regurgitant volume along with RV volume changes can help 
decide the optimal timing of pulmonary valve replacement 
(158, 159). LGE CMR may contribute to risk stratification, 
as well (160). However, in patients with a repaired tetralogy 
of Fallot, other factors should be assessed including 
tricuspid regurgitation, any residual VSD, branch pulmonary 
stenosis, aortic regurgitation and LV dysfunction (157). 
Therefore, a thorough evaluation of the left- and right-
sided ventricles and valves with an extension to branch 
pulmonary arteries and the ascending aorta should be made 
to manage patients with a repaired tetralogy of Fallot. 
Another important disease for which CMR can make great 
contributions to assessment is the Ebstein anomaly and the 
associated tricuspid regurgitation (161). Obtaining a stack 
of trans-axial cines is recommended, as well as horizontal 
four-chamber cines for complete visualization of the 
relationship between the right atrium and RV in patients 
with the Ebstein anomaly. A combination of these cine 
images is necessary for accurate and reproducible volume 
measurements of the functional RV in these patients, 
which is not easy to perform using short-axis cines (162). 
Tricuspid regurgitation is frequently accompanied and the 
quantification of its severity using phase contrast imaging 
is also an important integrated part of CMR evaluation in 
these patients. An ASD or patent foramen ovale is present 
in up to 50% of patients and should be sought with an 
atrial short-axis cine stack, although echocardiography is 
preferable to CMR for this purpose. Shunt volume can be 
quantified by phase-contrast imaging. 
Postoperative Follow-Up of Congenital Heart Disease 
Patients
Echocardiography is usually employed for the serial 
monitoring of congenital heart disease patients after 
surgery or the trans-catheter technique. In most cases, 
echocardiography is more than adequate, but in some cases, 
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accurate RV/LV volumes or regurgitant volume quantification 
is clinically important in deciding the optimal management. 
CMR can provide more accurate and reproducible ventricular 
volumes and function measurements than echocardiography 
(114, 163). This is especially true for the RV (164, 165), 
which is frequently involved and stressed by the repair 
of CHD (165). The sequential evaluation of pulmonary 
regurgitation and its effects on LV and RV functions should 
be comprehensively evaluated by CMR for effective patient 
management (166-168). The same strategy can be applied 
to patients with transposition of the great arteries who 
have undergone atrial and arterial switch operations, and 
patients with Fontan operations (149, 169-172). 
In congenital heart disease (protocols may 
include LV/RV mass and volumes, MR angiography, 
quantification of valvular disease, and LGE 
evaluation)
1.  Assessment about structure and hemodynamics 
of congenital heart disease including anomalies 
of coronary circulation, great vessels, and cardiac 
chambers and valves (Level of evidence: A, 
Appropriateness criteria: A)
2.  Assessment of post-operative structure and 
hemodynamics of congenital heart disease including 
ventricular, great arterial and valvular function 
and anatomy evaluation (Level of evidence: A, 
Appropriateness criteria: A)
Clinical Scenario 12: Patients with Valvular Heart Disease
Direct visualization of valvular anatomy and the 
cardiac chambers, and its hemodynamic consequences 
have been possible since the advent of 2D and Doppler 
echocardiography. There has been no doubt at all that 
echocardiography is the standard tool for the initial 
assessment and longitudinal follow-up of patients with 
valvular heart disease irrespective of native or prosthetic 
valves. Therefore, the role of CMR is strictly limited in the 
field of valvular heart disease in daily clinical practice. 
However, over the last 20 years, CMR has made remarkable 
improvements in its image quality, scan time, and even 
hemodynamic assessment and, as a result, it has emerged as 
an alternative noninvasive imaging modality that is without 
ionizing radiation exposure in patients with valvular 
diseases. Thanks to its excellent signal-to-noise ratio and 
good spatial resolution, CMR can provide beautiful images 
of the valve anatomy and can thus also provide valuable 
insight into the mechanisms of valvular lesions. Regurgitant 
or stenotic flow jets are well visualized on cine imaging 
without any contrast agent. However, jet size or density 
should not be used for qualitative evaluation of the severity 
of valvular disease. The visibility extent of any jet observed 
in cine CMR imaging does depend on the CMR setting of 
specific sequences. While CMR can quantify the severity of 
stenotic or regurgitant valve lesions via the phase contrast 
imaging technique, velocities can be underestimated if the 
scan slice is not optimally aligned to regurgitant or stenotic 
jets. In the evaluation of patients with valvular disease, the 
advantage of CMR is in its power to reveal consequences 
of the valvular lesion, including the effects on LV or RV 
volumes, systolic function and left atrial or right atrial 
volumes. More fascinating is the fact that all of these 
examinations can be performed without administration of 
contrast agents, and thus can be conducted in patients 
with renal failure without fear of nephrogenic systemic 
fibrosis. The SSFP cine pulse sequence is the most widely 
used CMR technique for investigating valve anatomy and 
motion. This pulse sequence is well known to have excellent 
blood-to-myocardium contrast and a high intrinsic signal-
to-noise ratio (173). With this technique, CMR can create 
tomographic images at any plane and at any level. Phase 
contrast imaging is used for velocity measurements and can 
be considered in patients whose echocardiographic images 
are inconclusive or inadequate for reliable evaluation. 
However, because temporal resolution of phase contrast 
imaging is much lower than Doppler echocardiography, we 
should consider a chance that the peak velocity will be 
underestimated. 
One thing that should be kept in mind is that almost 
all CMR validation studies in relation to valvular heart 
disease were performed with echocardiography as the gold 
standard and only in a small number of patients (174-
180). Nevertheless, the peak antegrade velocity, pressure 
gradient, and stenotic valve area can be accurately 
calculated with CMR in patients with valve stenosis. In 
addition, the regurgitant valve area, regurgitant volume 
and regurgitant fraction can be assessed in patients with 
valvular regurgitation. Like Doppler echocardiography, 
however, a misalignment of more than 20 degrees between 
the phase direction and the blood flow direction makes 
velocity measurements with CMR inaccurate (180). 
Reproducibility of LV and RV volume quantification is one 
of the most important strengths of CMR. Any significant 
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valvular regurgitation can cause LV or RV volume overload 
and can finally precipitate the LV or RV to remodel and 
change geometry. LV and RV volumes can be accurately 
measured with CMR without any assumption of ventricular 
geometry. This is especially useful for right-sided valve 
regurgitation, because echocardiography cannot accurately 
assess RV volume and ejection fraction due to its complex 
geometry and shape. In particular, pulmonary regurgitation, 
a major late complication after surgical correction of 
tetralogy of Fallot, has been frequently assessed using CMR-
based RV volume measurements (156, 164, 181, 182) and 
now CMR is generally accepted as the gold standard method 
for in vivo RV assessment (183, 184). Also, although CMR is 
safe in patients with prosthetic valves at 1.5-T, the metal 
contained within prosthetic valves generates artifacts 
and signal loss, and thus CMR validation in patients with 
prosthetic valves is very limited (185-187). Thus, as of now, 
the clinical use of CMR in valvular heart disease is limited. 
In this respect, the use of CMR in valve diseases is currently 
recommended only for patients with technically challenging 
echocardiographic images.
In valvular heart disease (protocols may include LV/
RV mass and volumes, MR angiography, quantification 
of valvular disease, and LGE evaluation)
1.  Characterization of native and prosthetic cardiac 
valves–including planimetry of stenotic disease and 
quantification of regurgitant disease/patients with 
technically limited images from transthoracic or 
transesophageal echocardiography (Level of evidence: 
A, Appropriateness criteria: A)
Clinical Scenario 13: Patients with Suspected or Diagnosed 
Myocardial Disease 
Myocardial diseases are one of the most important disease 
entities in the field of cardiology. They are usually classified 
into 2 categories, namely cardiomyopathy and myocarditis.
Cardiomyopathy
Cardiomyopathy is classified into 5 different categories, 
although there are definitely situations in which the 
suggested classification system cannot fully address some 
of the myopathic phenotypes. Unlike HCM and dilated 
cardiomyopathy (DCM), arrhythmogenic right ventricular 
dysplasia/cardiomyopathy (ARVD/C) is diagnosed on a 
histologic basis and characterized by progressive fibrofatty 
replacement in the RV, resulting in morphological and 
functional changes of the RV. ARVD/C can sometimes 
involve the LV and clinically manifests as a DCM phenotype, 
but this is not always true. 
Recently, the role of CMR has been significantly 
increased in the diagnosis of ARVD/C. Generally, the 
diagnosis of ARVD/C depends on the demonstration 
of structural, functional, ECG abnormalities, and their 
combinations. According to the original task force criteria, 
RV morphological and functional abnormalities were 
predominantly estimated by echocardiography. However, 
though useful, echocardiography is not the best approach 
for assessing morphological and functional changes in the 
RV. CMR is the gold standard for this purpose and thus, the 
revised task force criteria encompassed the CMR-derived 
definition of RV morphological and functional abnormalities 
including RV regional wall motion abnormalities, correct 
quantification of RV volumes, aneurysm/trabecular disarray, 
and increased myocardial signal suggestive of fatty 
replacement (188). However, the role of LGE CMR has not 
been mentioned in this new proposed criteria (188). CMR 
can allow for early detection of patients with genotype (+), 
but with phenotype (-) (189). In addition to its diagnostic 
role, CMR including LGE imaging can play a prognostic role 
in ARVD/C patients (190, 191). However, given that the 
normal variants of the RV are usually greater than those 
found in the LV, great caution should be exercised in the 
interpretation of RV findings found in CMR. 
As described in the heart failure section, CMR can be 
very helpful in the differential diagnosis or evaluation of 
specific cardiomyopathies, especially thanks to the advent 
of LGE imaging. Aside from ischemia-induced myocardial 
disease, the LGE pattern of non-ischemic cardiomyopathies 
usually spares the subendocardium, i.e., mid-wall or 
epicardial, and/or is inconsistent with a perfusion territory 
subtended by one coronary artery (124). The LGE pattern 
depends on the type of cardiomyopathy, though it is not 
always or totally differential (124). For example, it has 
been reported that cardiac amyloidosis has a typical LGE 
pattern, i.e., subendocardial, diffuse ring enhancement, 
with difficulty in determining optimal inversion time to 
null normal myocardium due to its characteristic diffuse 
involvement (128, 192), although the precise pattern 
of LGE in cardiac amyloidosis has been reported to be 
more variable in recent studies than what was previously 
believed (193, 194). However, LGE CMR is expected to 
facilitate the easy detection of cardiac involvement in 
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patients with sarcoidosis, and to be used in monitoring 
treatment responses because the degree of LGE is reduced 
with successful treatment of steroid therapy, suggesting the 
possibility that it may be used as a therapeutic surrogate 
marker (195). Trastuzumab-induced cardiomyopathy is 
characterized by LGE of the lateral wall of the LV within 
the mid myocardial portion (196), but this finding requires 
further data. LV noncompaction cardiomyopathy has been 
increasingly recognized along with the revolutionary 
evolution of cardiac imaging techniques. LV noncompaction 
cardiomyopathy is characterized by 2 factors; prominent LV 
trabeculae and deep inter-trabecular recesses (197). Since 
this cardiomyopathy can be diagnosed by LV morphologic 
features, the role of CMR has been increasingly important 
with its unprecedented high signal-to-noise ratio. A ratio 
of noncompacted/compacted myocardium of more than 
2.3 in diastole was suggested for the CMR diagnosis of 
this disease entity (198). CMR also precisely interrogates 
the transition zone between affected and non-affected 
LV segments due to its good spatial resolution. Stress-
induced cardiomyopathy was recently incorporated into 
cardiomyopathy classification, which is usually characterized 
by transient regional LV systolic dysfunction in the absence 
of obstructive epicardial coronary disease on coronary 
angiography. In most cases, the LV apex is involved, but 
sometimes the mid-ventricle or basal ventricle alone can be 
affected. Although echocardiography is usually enough for 
the diagnosis of stress-induced cardiomyopathy, CMR seems 
to be a promising imaging modality for confirming regional 
wall motion abnormality and for differentiating this (no LGE 
is present in most cases) from acute myocardial infarction 
or myocarditis (LGE is frequently present) based on the 
presence or absence of LGE (199-201). 
Myocarditis
Myocarditis is another important myocardial disease 
of which a diagnosis is not easy to make. The gold 
standard method of diagnosis is histologic confirmation 
of myocardial inflammation, which is sometimes difficult 
and limited by the patchy involvement of the inflammatory 
process. Myocardial biopsy carries some risk, as well. The 
unique ability of CMR to visualize myocardial tissue changes 
is the reason for CMR being increasingly employed in the 
diagnostic process of myocarditis (202, 203). Anticipated 
tissue pathological changes in acute myocarditis include 
intracellular/interstitial edema, hyperemia, capillary 
leakage, and cellular necrosis with fibrosis, all of which 
can be easily found with a variety of CMR techniques like 
T2 edema imaging and LGE or the early enhancement 
technique. CMR can show increases in myocardial signals 
on T2-weighted and LGE images in acute myocarditis (129, 
130). 
For the accurate diagnosis of cardiomyopathy etiology, 
the role of CMR is increasingly recognized and emphasized. 
There is no doubt that the gold standard method for 
etiological diagnosis is histological confirmation and the 
first-line imaging modality in patients under suspicion 
for myocardial disease is echocardiography. However, a 
comprehensive CMR protocol including cine, LGE, and 
sometimes perfusion techniques can provide etiological 
diagnosis and prognostic implications. 
In suspected or diagnosed myocardial disease 
(protocols may include LV/RV mass and volumes, MR 
angiography, quantification of valvular disease, and 
LGE evaluation)
1.  Evaluation for ARVD/C patients presenting with 
syncope or ventricular arrhythmia (Level of evidence: 
A, Appropriateness criteria: A)
2.  Evaluation of myocarditis or myocardial infarction 
with normal coronary arteries/positive cardiac 
enzymes without obstructive atherosclerosis on 
angiography (Level of evidence: A, Appropriateness 
criteria: A)
3.  Evaluation of specific cardiomyopathies (infiltrative 
[amyloid, sarcoid, etc.] or due to cardiotoxic 
therapies) (Level of evidence: A, Appropriateness 
criteria: A)
Clinical Scenario 14: Evaluation in Patients with HCM 
Hypertrophic cardiomyopathy is the most common 
genetic cardiovascular disorder that is characterized by 
sarcomere gene mutation (204). Accurate diagnosis of HCM 
is crucial because HCM patients must alter their life-style 
to prevent unexpected dismal events. Family screening 
should be done, as well. Transthoracic echocardiography 
is the most commonly used imaging modality for the 
diagnosis of HCM by identification of LV hypertrophy and 
systolic anterior motion of the mitral valve with associated 
LV outflow tract dynamic obstruction. CMR, thanks to its 
high signal-to-noise ratio and good spatial resolution, 
has established its role in the diagnosis of HCM, because 
phenotypic expressions of HCM are diverse and complex, 
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and thus transthoracic echocardiography sometimes 
misses the hypertrophic segments, especially in the apex, 
posteroseptum and lateral free wall, difficult areas to 
evaluate with transthoracic echocardiography due to its low 
lateral spatial resolution (205-208). The LV apex is notably 
much more difficult to evaluate with echocardiography 
due in part to its proximity to the echocardiographic 
probe. Thus, diagnosis of apical HCM may be underreported 
using transthoracic echocardiography (207). In addition, 
the detection of apical aneurysm is problematic with 
transthoracic echocardiography. However, a more sensitive 
discovery of apical aneurysm in HCM is clinically relevant, 
given that its prevalence is not low and that its presence 
is associated with cardiovascular morbidity and mortality 
(209, 210). In this respect, cine CMR can provide more 
accurate information about the LV hypertrophic pattern and 
the presence or absence of apical aneurysm in HCM patients 
whose echocardiographic images are technically suboptimal 
and nondiagnostic. The phenotypic heterogeneity of HCM 
sometimes involves morphologic abnormalities of the RV, 
which can be assessed with cine CMR more accurately than 
with transthoracic echocardiography, although the clinical 
or prognostic significance of RV involvement in HCM is yet 
to be determined (211).
Late gadolinium enhancement CMR can provide a unique 
opportunity for patients with unexplained LV hypertrophy 
(212). LGE in HCM is predominantly located at the anterior 
and posterior insertion points of the RV into the septum 
with a typical non-subendocardial pattern (212). However, 
LGE can be found in different locations, not confined 
to hypertrophic segments (126). Myocardial fibrosis is 
generally accepted as the main pathohistological feature 
of HCM, which can be accurately assessed with LGE CMR 
(213-215). CMR-determined myocardial fibrosis has been 
repeatedly reported to be closely associated with a grave 
prognosis in HCM patients and has advantages over 
traditional risk factors for future sudden death (209, 216-
221). Also, the extent of LGE is reported to be linked to 
progressive ventricular remodeling (222). Given the strong 
association between the presence of LGE and ventricular 
tachyarrhythmia on Holter monitoring (209, 220, 223), it is 
conceivable that LGE in HCM can be a potential arbitrator 
of ventricular tachyarrhythmia. Although LGE CMR looks 
promising, there still seems to be insufficient data for 
inserting ICDs in HCM patients based only on LGE CMR 
findings, given the technical and methodological issues of 
LGE assessment (224).
Hypertrophic cardiomyopathy is a genetic disease 
with an autosomal dominant trait, and thus first-degree 
relatives have a 50% chance of being gene carriers. 
Although genotyping is the best way to detect possible 
future clinical manifestations of HCM, it is limited by high 
cost and the variable penetrance of the disease. Another 
problem is that approximately 40% of HCM patients are 
genetically negative. Therefore, the most realistic screening 
modalities that can be applied clinically are the ECG and 
echocardiogram. However, some CMR findings have recently 
been found to suggest early imaging manifestations of HCM 
including myocardial crypts (225, 226), elongated mitral 
valve leaflets (227), and the presence of LGE suggesting 
HCM (228). All of these findings should be confirmed in 
future CMR studies, but if combined with genetic testing, 
these CMR evaluations have the potential to identify HCM 
at an early stage of the disease. Current and emerging 
recommendations of CMR are summarized in the following 
table.
Evaluation in HCM
1.  In HCM patients with inconclusive or inadequate 
echocardiography (Level of evidence: A, 
Appropriateness criteria: A)
2.  To define apical hypertrophy and/or aneurysm if 
echocardiography is inconclusive (Level of evidence: 
A, Appropriateness criteria: A)
3.  In selected patients with known HCM, when sudden 
cardiac death risk stratification is inconclusive after 
documentation of the conventional risk factors/use of 
LGE evaluation (Level of evidence: A, Appropriateness 
criteria: A)
Miscellaneous Disease
Clinical Scenario 15: Evaluation of Cardiac Mass 
(Suspected Tumor or Thrombus)/Use of Contrast for 
Perfusion and Enhancement
Intracardiac mass is not uncommonly seen in clinical 
situations with the thrombus being the most common 
intracardiac mass. Notably, a left atrial thrombus in patients 
with atrial fibrillation and a LV thrombus in patients with 
severe LV systolic dysfunction due to myocardial infarction 
or underlying cardiomyopathy are frequently discovered. 
Several previous studies show that the detection rate 
of an intracardiac thrombus especially the LV thrombus 
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using LGE imaging with varying degrees of inversion time 
is better than that of conventional echocardiography or 
contrast echocardiography (229-231). The intramural type 
of LV thrombus is especially best detected by contrast CMR 
(232). Regarding intracardiac tumors, the most important 
information provided by CMR is extent of tumor and its 
relationship with adjacent structures. Although malignant 
tumors are rare, tissue characterization of a tumor would 
reveal the nature of the tumor. Myxoma is the most common 
intracardiac tumor and CMR findings of cardiac myxoma 
show increased signal intensity in T2-weighted images 
but the signal composition is usually heterogeneous. The 
differential diagnosis of a high signal intensity lesion on 
T1-weighted images includes lipoma, tumor with recent 
hemorrhage, and melanoma (due to the effects of melanin). 
For the accurate differentiation in this situation, fat 
saturation technique provides additional information. A 
lesion with low signal intensity on T1-weighted images may 
represent a cyst, a signal void in a vascular malformation, 
a calcified lesion or the presence of air. As water content 
typically shows high signal intensity on T2-weighted 
images, intracardiac or pericardial cyst provides high signal 
intensity. In addition, myxoma, lipoma or metastatic tumor 
can also be shown to have high signal intensity on T2-
weighted images. So, for further differentiation, perfusion 
imaging, early and late gadolinium enhancement imagings 
are usually needed. In the early phase, after injection at 
1–2 minutes, necrotic areas in malignant tumors show 
up as dark areas surrounded by enhancement elsewhere. 
In the later phase, malignant tumors typically show 
contrast enhancement indicating tissue vascularity. Such 
enhancement pattern is usually absent in cystic lesions 
and most benign tumors except for myxomas (2, 3). For 
the differentiation from myxoma, its location and presence 
of stalk would provide important information. Adjacent 
tissue infiltration is best estimated by CMR using first pass 
perfusion imaging and the LGE technique (233-235).
Evaluation of cardiac mass (suspected tumor 
or thrombus)/use of contrast for perfusion and 
enhancement (Level of evidence: A, Appropriateness 
criteria: A)
Clinical Scenario 16: Evaluation of Pericardium 
Cardiac magnetic resonance can provide information about 
the accurate amount of pericardial effusion and pericardial 
thickness (236, 237). Using LGE with fat saturation 
techniques, the degree of pericardial inflammation can 
be assumed in patients with constrictive pericarditis. 
Therefore it can predict the effectiveness of intensive 
anti-inflammatory medications before a pericardiectomy 
(238). Pericardial tumors are also detected and their tissue 
characterization is also possible with good reliability. The 
absence of the pericardium can be suspected by a leftward 
shift of the long axis LV. Any protrusion of any portion of 
the heart can suggest pericardial absence (239).
Evaluation of pericardium (pericardial mass, constrictive 
pericarditis) (Level of evidence: B, Appropriateness 
criteria: A)
Clinical Scenario 17: Evaluation for Aortic Dissection
MR angiography has been accepted as a good modality 
for detecting a dissection flap and entry tear site. 
Transesophageal echocardiography or CT scans are widely 
used modalities. However the aortic arch is a weak point 
with transesophageal echocardiography and CT scans 
need iodine contrast agents and radiation. A previous 
study shows that cardiac CT or CMR have advantages over 
transthoracic echocardiography. In a meta-analysis of 1139 
patients, the pooled sensitivity (98–100%) and specificity 
(95–98%) were comparable between these imaging 
techniques. The pooled positive likelihood ratio appeared 
to be higher for CMR (positive likelihood ratio, 25.3; 95% 
CI [11.1–57.1]) than for transesophageal echocardiography 
(14.1; 6.0–33.2) or helical CT (13.9; 4.2–46.0) (240). 
Evaluation for aortic dissection (Level of evidence: A, 
Appropriateness criteria: A)
Clinical Scenario 18: Evaluation of Pulmonary Veins 
Prior to Radiofrequency Ablation for Atrial Fibrillation/
Left Atrial and Pulmonary Venous Anatomy Including 
Dimensions of Veins for Mapping Purposes
An accurate anatomic view of the left atrium and 
pulmonary veins is essential before radiofrequency ablation 
of pulmonary veins in patients with atrial fibrillation. 
Currently cardiac CT provides excellent images to guide 
catheter-based pulmonic vein isolation, and CMR can also 
provide excellent imaging views about anatomical variants 
of the pulmonic vein (241-243). Some studies have reported 
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that diverse variations of the pulmonic vein exist and these 
have been well correlated with cardiac CT and CMR (241).
Evaluation of pulmonary veins prior to radiofrequency 
ablation for atrial fibrillation/left atrial and 
pulmonary venous anatomy including dimensions of 
veins for mapping purposes (Level of evidence: B, 
Appropriateness criteria: A)
Clinical Scenario 19: Anatomic Assessment before 
Percutaneous Device Closure of ASD or VSD/Anatomic 
Assessment before Percutaneous Aortic Valve Replacement 
The accurate measurement of ASD shape and size is 
essential in the selection of an appropriate device. Accurate 
classification of the ASD type, non-invasive measurement 
of Qp/Qs (pulmonary flow/systemic flow ratio), and 
detection of concomitant congenital anomaly are extremely 
important and can be reliably done by CMR. Several 
studies have shown that CMR based ASD correlated well to 
transesophageal echocardiography based on defects size. En 
face CMR with an optimized imaging plane can determine 
ASD flow, size, and morphology (244, 245). Thomson et al. 
(246) reported that CMR provided information incremental 
to comprehensive standard evaluation that altered clinical 
management in 20% of patients. Recently, the catheter-
based percutaneous aortic valve replacement has been 
introduced and the number of this procedure being 
performed has increased markedly. While transesophageal 
echocardiography and cardiac CT are known to provide 
excellent anatomical and functional images of the left 
ventricular outflow tract, the relationship to the coronary 
ostium, and the severity of calcification, CMR has been 
reported to provide good information albeit with a tendency 
to have larger values than transthoracic echocardiography 
for all measurements (247).
Anatomic assessment before percutaneous device 
closure of ASD or VSD/anatomic assessment before 
percutaneous aortic valve replacement (Level of 
evidence: B, Appropriateness criteria: A)
Acknowledgments
Rating Panel: Dae-Hee Kim, Kye Hun Kim, Sung-A Chang, 
Seong-Mi Park, Hyuk-Jae Chang, Wook Jin Chung, Hae-
Ok Jung, Sang-Chol Lee, Jong-Won Ha, Jun Kwan, Eun Joo 
Kang, Joon-Won Kang, Sung Min Ko, Hyon Joo Kwag, Yon Mi 
Sung, Whal Lee, Ki-Seuk Choo, Sang Il Choi, Jung Im Jung, 
Heon Lee
Consultation Panel: Euisoo Shin, Ein-Soon Shin
Review Panel: Seung-Pyo Lee, Il-Suk Sohn, Ho-Joong 
Yoon, Jae Seung Seo, Jong-Min Lee, Byoung Wook Choi, 
Chung Il Noh, Lucy Young Min Eun, Gi Beom Kim, Ein-Soon 
Shin
Steering Committee: Yong-Jin Kim, Sang-Chol Lee, Tae 
Hoon Kim, Yeon Hyeon Choe, Dae-Won Sohn
Supplementary Materials
The online-only Data Supplement is available with this 
article at http://dx.doi.org/10.3348/kjr.2014.15.6.659.
REFERENCES
1. Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, 
Kiess M, et al. CCS/CAR/CANM/CNCS/CanSCMR joint position 
statement on advanced noninvasive cardiac imaging using 
positron emission tomography, magnetic resonance imaging 
and multidetector computed tomographic angiography in 
the diagnosis and evaluation of ischemic heart disease--
executive summary. Can J Cardiol 2007;23:107-119
2. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, 
Pohost GM, Rademakers FE, et al. Clinical indications for 
cardiovascular magnetic resonance (CMR): Consensus Panel 
report. Eur Heart J 2004;25:1940-1965
3. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, 
Pohost GM, Rademakers FE, et al. Clinical indications for 
cardiovascular magnetic resonance (CMR): Consensus Panel 
report. J Cardiovasc Magn Reson 2004;6:727-765
4. ASCI CCT and CMR Guideline Working Group, Kitagawa 
K, Choi BW, Chan C, Jinzaki M, Tsai IC, et al. ASCI 2010 
appropriateness criteria for cardiac magnetic resonance 
imaging: a report of the Asian Society of Cardiovascular 
Imaging cardiac computed tomography and cardiac magnetic 
resonance imaging guideline working group. Int J Cardiovasc 
Imaging 2010;26 Suppl 2:173-186
5. Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, 
Carr JC, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/
SIR 2006 appropriateness criteria for cardiac computed 
tomography and cardiac magnetic resonance imaging: a 
report of the American College of Cardiology Foundation 
Quality Strategic Directions Committee Appropriateness 
Criteria Working Group, American College of Radiology, 
Society of Cardiovascular Computed Tomography, Society 
for Cardiovascular Magnetic Resonance, American Society 
of Nuclear Cardiology, North American Society for Cardiac 
Imaging, Society for Cardiovascular Angiography and 
Interventions, and Society of Interventional Radiology. J Am 
679
Appropriate Use Criteria for CMR
Korean J Radiol 15(6), Nov/Dec 2014kjronline.org
Coll Cardiol 2006;48:1475-1497
6. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link 
MS, et al. 2011 ACCF/AHA guideline for the diagnosis 
and treatment of hypertrophic cardiomyopathy: executive 
summary: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on 
Practice Guidelines. Circulation 2011;124:2761-2796
7. Patel MR, White RD, Abbara S, Bluemke DA, Herfkens RJ, 
Picard M, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR 
appropriate utilization of cardiovascular imaging in heart 
failure: a joint report of the American College of Radiology 
Appropriateness Criteria Committee and the American College 
of Cardiology Foundation Appropriate Use Criteria Task Force. 
J Am Coll Cardiol 2013;61:2207-2231
8. Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O’Gara 
P, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/
SCMR 2010 appropriate use criteria for cardiac computed 
tomography. A report of the American College of Cardiology 
Foundation Appropriate Use Criteria Task Force, the Society of 
Cardiovascular Computed Tomography, the American College 
of Radiology, the American Heart Association, the American 
Society of Echocardiography, the American Society of Nuclear 
Cardiology, the North American Society for Cardiovascular 
Imaging, the Society for Cardiovascular Angiography and 
Interventions, and the Society for Cardiovascular Magnetic 
Resonance. J Am Coll Cardiol 2010;56:1864-1894
9. Wilke N, Jerosch-Herold M, Wang Y, Huang Y, Christensen BV, 
Stillman AE, et al. Myocardial perfusion reserve: assessment 
with multisection, quantitative, first-pass MR imaging. 
Radiology 1997;204:373-384
10. Schwitter J, Nanz D, Kneifel S, Bertschinger K, Büchi 
M, Knüsel PR, et al. Assessment of myocardial perfusion 
in coronary artery disease by magnetic resonance: a 
comparison with positron emission tomography and coronary 
angiography. Circulation 2001;103:2230-2235
11. Giang TH, Nanz D, Coulden R, Friedrich M, Graves M, Al-
Saadi N, et al. Detection of coronary artery disease by 
magnetic resonance myocardial perfusion imaging with 
various contrast medium doses: first European multi-centre 
experience. Eur Heart J 2004;25:1657-1665
12. Pilz G, Bernhardt P, Klos M, Ali E, Wild M, Höfling B. 
Clinical implication of adenosine-stress cardiac magnetic 
resonance imaging as potential gatekeeper prior to invasive 
examination in patients with AHA/ACC class II indication for 
coronary angiography. Clin Res Cardiol 2006;95:531-538
13. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, 
Everett CC, et al. Cardiovascular magnetic resonance and 
single-photon emission computed tomography for diagnosis 
of coronary heart disease (CE-MARC): a prospective trial. 
Lancet 2012;379:453-460
14. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-
Saadi N, Ahlstrom H, et al. MR-IMPACT: comparison of 
perfusion-cardiac magnetic resonance with single-photon 
emission computed tomography for the detection of coronary 
artery disease in a multicentre, multivendor, randomized 
trial. Eur Heart J 2008;29:480-489
15. Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle 
K, et al. MR-IMPACT II: Magnetic Resonance Imaging for 
Myocardial Perfusion Assessment in Coronary artery disease 
Trial: perfusion-cardiac magnetic resonance vs. single-photon 
emission computed tomography for the detection of coronary 
artery disease: a comparative multicentre, multivendor trial. 
Eur Heart J 2013;34:775-781
16. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, 
Carlos RC. Diagnostic performance of stress cardiac magnetic 
resonance imaging in the detection of coronary artery 
disease: a meta-analysis. J Am Coll Cardiol 2007;50:1343-
1353
17. Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle 
K, et al. Superior diagnostic performance of perfusion-
cardiovascular magnetic resonance versus SPECT to detect 
coronary artery disease: the secondary endpoints of the 
multicenter multivendor MR-IMPACT II (Magnetic Resonance 
Imaging for Myocardial Perfusion Assessment in Coronary 
Artery Disease Trial). J Cardiovasc Magn Reson 2012;14:61
18. Paetsch I, Jahnke C, Ferrari VA, Rademakers FE, Pellikka PA, 
Hundley WG, et al. Determination of interobserver variability 
for identifying inducible left ventricular wall motion 
abnormalities during dobutamine stress magnetic resonance 
imaging. Eur Heart J 2006;27:1459-1464
19. Hundley WG, Hamilton CA, Thomas MS, Herrington DM, Salido 
TB, Kitzman DW, et al. Utility of fast cine magnetic resonance 
imaging and display for the detection of myocardial ischemia 
in patients not well suited for second harmonic stress 
echocardiography. Circulation 1999;100:1697-1702
20. Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, 
et al. Noninvasive diagnosis of ischemia-induced wall motion 
abnormalities with the use of high-dose dobutamine stress 
MRI: comparison with dobutamine stress echocardiography. 
Circulation 1999;99:763-770
21. Paetsch I, Jahnke C, Wahl A, Gebker R, Neuss M, Fleck E, et 
al. Comparison of dobutamine stress magnetic resonance, 
adenosine stress magnetic resonance, and adenosine stress 
magnetic resonance perfusion. Circulation 2004;110:835-842
22. Pennell DJ, Underwood SR, Manzara CC, Swanton RH, 
Walker JM, Ell PJ, et al. Magnetic resonance imaging during 
dobutamine stress in coronary artery disease. Am J Cardiol 
1992;70:34-40
23. Rerkpattanapipat P, Gandhi SK, Darty SN, Williams RT, Davis 
AD, Mazur W, et al. Feasibility to detect severe coronary 
artery stenoses with upright treadmill exercise magnetic 
resonance imaging. Am J Cardiol 2003;92:603-606
24. Schalla S, Klein C, Paetsch I, Lehmkuhl H, Bornstedt A, 
Schnackenburg B, et al. Real-time MR image acquisition 
during high-dose dobutamine hydrochloride stress for 
detecting left ventricular wall-motion abnormalities 
in patients with coronary arterial disease. Radiology 
2002;224:845-851
25. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi 
WA, et al. Detection of myocardial damage in patients with 
sarcoidosis. Circulation 2009;120:1969-1977
26. Wahl A, Paetsch I, Gollesch A, Roethemeyer S, Foell 
680
Yoon et al.
Korean J Radiol 15(6), Nov/Dec 2014 kjronline.org
D, Gebker R, et al. Safety and feasibility of high-dose 
dobutamine-atropine stress cardiovascular magnetic 
resonance for diagnosis of myocardial ischaemia: experience 
in 1000 consecutive cases. Eur Heart J 2004;25:1230-1236
27. Kuijpers D, Ho KY, van Dijkman PR, Vliegenthart R, Oudkerk 
M. Dobutamine cardiovascular magnetic resonance for the 
detection of myocardial ischemia with the use of myocardial 
tagging. Circulation 2003;107:1592-1597
28. Korosoglou G, Lehrke S, Wochele A, Hoerig B, Lossnitzer 
D, Steen H, et al. Strain-encoded CMR for the detection 
of inducible ischemia during intermediate stress. JACC 
Cardiovasc Imaging 2010;3:361-371
29. Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, 
et al. Coronary magnetic resonance angiography for the 
detection of coronary stenoses. N Engl J Med 2001;345:1863-
1869
30. Sakuma H, Ichikawa Y, Chino S, Hirano T, Makino K, Takeda 
K. Detection of coronary artery stenosis with whole-heart 
coronary magnetic resonance angiography. J Am Coll Cardiol 
2006;48:1946-1950
31. Kato S, Kitagawa K, Ishida N, Ishida M, Nagata M, Ichikawa Y, 
et al. Assessment of coronary artery disease using magnetic 
resonance coronary angiography: a national multicenter trial. 
J Am Coll Cardiol 2010;56:983-991
32. Yang Q, Li K, Liu X, Bi X, Liu Z, An J, et al. Contrast-enhanced 
whole-heart coronary magnetic resonance angiography at 
3.0-T: a comparative study with X-ray angiography in a single 
center. J Am Coll Cardiol 2009;54:69-76
33. Hamdan A, Asbach P, Wellnhofer E, Klein C, Gebker R, Kelle 
S, et al. A prospective study for comparison of MR and CT 
imaging for detection of coronary artery stenosis. JACC 
Cardiovasc Imaging 2011;4:50-61
34. Schuetz GM, Zacharopoulou NM, Schlattmann P, Dewey M. 
Meta-analysis: noninvasive coronary angiography using 
computed tomography versus magnetic resonance imaging. 
Ann Intern Med 2010;152:167-177
35. Nagata M, Kato S, Kitagawa K, Ishida N, Nakajima H, 
Nakamori S, et al. Diagnostic accuracy of 1.5-T unenhanced 
whole-heart coronary MR angiography performed with 
32-channel cardiac coils: initial single-center experience. 
Radiology 2011;259:384-392
36. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, 
Rerkpattanapipat P, Link KM. Magnetic resonance 
imaging determination of cardiac prognosis. Circulation 
2002;106:2328-2333
37. Jahnke C, Nagel E, Gebker R, Kokocinski T, Kelle S, Manka R, 
et al. Prognostic value of cardiac magnetic resonance stress 
tests: adenosine stress perfusion and dobutamine stress wall 
motion imaging. Circulation 2007;115:1769-1776
38. Gargiulo P, Dellegrottaglie S, Bruzzese D, Savarese G, Scala 
O, Ruggiero D, et al. The prognostic value of normal stress 
cardiac magnetic resonance in patients with known or 
suspected coronary artery disease: a meta-analysis. Circ 
Cardiovasc Imaging 2013;6:574-582
39. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M. 
Prognostic value of stress cardiac magnetic resonance 
imaging in patients with known or suspected coronary artery 
disease: a systematic review and meta-analysis. J Am Coll 
Cardiol 2013;62:826-838
40. Yoon YE, Kitagawa K, Kato S, Ishida M, Nakajima H, Kurita 
T, et al. Prognostic value of coronary magnetic resonance 
angiography for prediction of cardiac events in patients 
with suspected coronary artery disease. J Am Coll Cardiol 
2012;60:2316-2322
41. Cheitlin MD, De Castro CM, McAllister HA. Sudden death 
as a complication of anomalous left coronary origin from 
the anterior sinus of Valsalva, A not-so-minor congenital 
anomaly. Circulation 1974;50:780-787
42. Bunce NH, Lorenz CH, Keegan J, Lesser J, Reyes EM, Firmin 
DN, et al. Coronary artery anomalies: assessment with free-
breathing three-dimensional coronary MR angiography. 
Radiology 2003;227:201-208
43. Gharib AM, Ho VB, Rosing DR, Herzka DA, Stuber M, Arai 
AE, et al. Coronary artery anomalies and variants: technical 
feasibility of assessment with coronary MR angiography at 3 T. 
Radiology 2008;247:220-227
44. McConnell MV, Ganz P, Selwyn AP, Li W, Edelman RR, 
Manning WJ. Identification of anomalous coronary arteries 
and their anatomic course by magnetic resonance coronary 
angiography. Circulation 1995;92:3158-3162
45. Taylor AM, Thorne SA, Rubens MB, Jhooti P, Keegan J, 
Gatehouse PD, et al. Coronary artery imaging in grown up 
congenital heart disease: complementary role of magnetic 
resonance and x-ray coronary angiography. Circulation 
2000;101:1670-1678
46. Casolo G, Del Meglio J, Rega L, Manta R, Margheri M, Villari 
N, et al. Detection and assessment of coronary artery 
anomalies by three-dimensional magnetic resonance coronary 
angiography. Int J Cardiol 2005;103:317-322
47. Clemente A, Del Borrello M, Greco P, Mannella P, Di Gregorio 
F, Romano S, et al. Anomalous origin of the coronary arteries 
in children: diagnostic role of three-dimensional coronary MR 
angiography. Clin Imaging 2010;34:337-343
48. Plein S, Greenwood JP, Ridgway JP, Cranny G, Ball SG, 
Sivananthan MU. Assessment of non-ST-segment elevation 
acute coronary syndromes with cardiac magnetic resonance 
imaging. J Am Coll Cardiol 2004;44:2173-2181
49. Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, 
Davis J, et al. Detecting acute coronary syndrome in the 
emergency department with cardiac magnetic resonance 
imaging. Circulation 2003;107:531-537
50. Cury RC, Shash K, Nagurney JT, Rosito G, Shapiro MD, 
Nomura CH, et al. Cardiac magnetic resonance with T2-
weighted imaging improves detection of patients with acute 
coronary syndrome in the emergency department. Circulation 
2008;118:837-844
51. Miller CD, Hwang W, Case D, Hoekstra JW, Lefebvre C, 
Blumstein H, et al. Stress CMR imaging observation unit in 
the emergency department reduces 1-year medical care costs 
in patients with acute chest pain: a randomized study for 
comparison with inpatient care. JACC Cardiovasc Imaging 
2011;4:862-870
681
Appropriate Use Criteria for CMR
Korean J Radiol 15(6), Nov/Dec 2014kjronline.org
52. Miller CD, Case LD, Little WC, Mahler SA, Burke GL, Harper 
EN, et al. Stress CMR reduces revascularization, hospital 
readmission, and recurrent cardiac testing in intermediate-
risk patients with acute chest pain. JACC Cardiovasc Imaging 
2013;6:785-794
53. Kern MJ, Lerman A, Bech JW, De Bruyne B, Eeckhout E, 
Fearon WF, et al. Physiological assessment of coronary artery 
disease in the cardiac catheterization laboratory: a scientific 
statement from the American Heart Association Committee 
on Diagnostic and Interventional Cardiac Catheterization, 
Council on Clinical Cardiology. Circulation 2006;114:1321-
1341
54. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern 
MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update 
for percutaneous coronary intervention: a report of the 
American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing 
Committee to Update 2001 Guidelines for Percutaneous 
Coronary Intervention). Circulation 2006;113:e166-e286
55. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern 
MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update 
for percutaneous coronary intervention: a report of the 
American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing 
Committee to Update the 2001 Guidelines for Percutaneous 
Coronary Intervention). J Am Coll Cardiol 2006;47:e1-e121
56. Meijboom WB, Van Mieghem CA, van Pelt N, Weustink A, 
Pugliese F, Mollet NR, et al. Comprehensive assessment of 
coronary artery stenoses: computed tomography coronary 
angiography versus conventional coronary angiography and 
correlation with fractional flow reserve in patients with 
stable angina. J Am Coll Cardiol 2008;52:636-643
57. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t 
Veer M, et al. Fractional flow reserve versus angiography for 
guiding percutaneous coronary intervention. N Engl J Med 
2009;360:213-224
58. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, 
Bornschein B, et al. Fractional flow reserve versus 
angiography for guiding percutaneous coronary intervention 
in patients with multivessel coronary artery disease: 2-year 
follow-up of the FAME (Fractional Flow Reserve Versus 
Angiography for Multivessel Evaluation) study. J Am Coll 
Cardiol 2010;56:177-184
59. Hamon M, Fau G, Née G, Ehtisham J, Morello R, Hamon 
M. Meta-analysis of the diagnostic performance of stress 
perfusion cardiovascular magnetic resonance for detection of 
coronary artery disease. J Cardiovasc Magn Reson 2010;12:29
60. Rieber J, Huber A, Erhard I, Mueller S, Schweyer M, Koenig 
A, et al. Cardiac magnetic resonance perfusion imaging 
for the functional assessment of coronary artery disease: a 
comparison with coronary angiography and fractional flow 
reserve. Eur Heart J 2006;27:1465-1471
61. Costa MA, Shoemaker S, Futamatsu H, Klassen C, Angiolillo 
DJ, Nguyen M, et al. Quantitative magnetic resonance 
perfusion imaging detects anatomic and physiologic coronary 
artery disease as measured by coronary angiography and 
fractional flow reserve. J Am Coll Cardiol 2007;50:514-522
62. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, 
McLaughlin MJ, et al. Validation of magnetic resonance 
myocardial perfusion imaging with fractional flow reserve 
for the detection of significant coronary heart disease. 
Circulation 2009;120:2207-2213
63. Lockie T, Ishida M, Perera D, Chiribiri A, De Silva K, Kozerke 
S, et al. High-resolution magnetic resonance myocardial 
perfusion imaging at 3.0-Tesla to detect hemodynamically 
significant coronary stenoses as determined by fractional 
flow reserve. J Am Coll Cardiol 2011;57:70-75
64. Groothuis JG, Beek AM, Brinckman SL, Meijerink MR, van 
den Oever ML, Hofman MB, et al. Combined non-invasive 
functional and anatomical diagnostic work-up in clinical 
practice: the magnetic resonance and computed tomography 
in suspected coronary artery disease (MARCC) study. Eur 
Heart J 2013;34:1990-1998
65. Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, 
Nagel E, et al. Diagnostic performance of noninvasive 
myocardial perfusion imaging using single-photon emission 
computed tomography, cardiac magnetic resonance, and 
positron emission tomography imaging for the detection of 
obstructive coronary artery disease: a meta-analysis. J Am 
Coll Cardiol 2012;59:1719-1728
66. Bryan AJ, Angelini GD. The biology of saphenous vein graft 
occlusion: etiology and strategies for prevention. Curr Opin 
Cardiol 1994;9:641-649
67. Barner HB, Standeven JW, Reese J. Twelve-year experience 
with internal mammary artery for coronary artery bypass. J 
Thorac Cardiovasc Surg 1985;90:668-675
68. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after 
coronary artery bypass surgery: predictors and prognosis 
(CASS Registry). Coronary Artery Surgery Study. J Am Coll 
Cardiol 1995;26:895-899
69. Langerak SE, Vliegen HW, de Roos A, Zwinderman AH, Jukema 
JW, Kunz P, et al. Detection of vein graft disease using high-
resolution magnetic resonance angiography. Circulation 
2002;105:328-333
70. Galjee MA, van Rossum AC, Doesburg T, van Eenige MJ, 
Visser CA. Value of magnetic resonance imaging in assessing 
patency and function of coronary artery bypass grafts. An 
angiographically controlled study. Circulation 1996;93:660-
666
71. Duerinckx AJ, Atkinson D, Hurwitz R. Assessment of coronary 
artery patency after stent placement using magnetic 
resonance angiography. J Magn Reson Imaging 1998;8:896-
902
72. Sardanelli F, Zandrino F, Molinari G, Iozzelli A, Balbi M, 
Barsotti A. MR evaluation of coronary stents with navigator 
echo and breath-hold cine gradient-echo techniques. Eur 
Radiol 2002;12:193-200
73. De Cobelli F, Cappio S, Vanzulli A, Del Maschio A. MRI 
assessment of coronary stents. Rays 1999;24:140-148
74. Duerinckx AJ, Atkinson D, Hurwitz R, Mintorovitch J, 
Whitney W. Coronary MR angiography after coronary stent 
placement. AJR Am J Roentgenol 1995;165:662-664
682
Yoon et al.
Korean J Radiol 15(6), Nov/Dec 2014 kjronline.org
75. De Cobelli F, Guidetti D, Vanzulli A, Mellone R, Chierchia S, 
Del Maschio A. [Magnetic resonance angiography of coronary 
arteries: assessment in patients with coronary stenosis and 
control after stent positioning]. Radiol Med 1998;95:54-61
76. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof 
E, Fleischmann KE, et al. ACC/AHA 2007 Guidelines on 
Perioperative Cardiovascular Evaluation and Care for 
Noncardiac Surgery: Executive Summary: A Report of the 
American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (Writing Committee to 
Revise the 2002 Guidelines on Perioperative Cardiovascular 
Evaluation for Noncardiac Surgery): Developed in 
Collaboration With the American Society of Echocardiography, 
American Society of Nuclear Cardiology, Heart Rhythm 
Society, Society of Cardiovascular Anesthesiologists, Society 
for Cardiovascular Angiography and Interventions, Society 
for Vascular Medicine and Biology, and Society for Vascular 
Surgery. Circulation 2007;116:1971-1996
77. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof 
EL, Fleischmann KE, et al. ACC/AHA 2007 guidelines 
on perioperative cardiovascular evaluation and care for 
noncardiac surgery: a report of the American College of 
Cardiology/American Heart Association Task Force on 
Practice Guidelines (Writing Committee to Revise the 2002 
Guidelines on Perioperative Cardiovascular Evaluation for 
Noncardiac Surgery) developed in collaboration with the 
American Society of Echocardiography, American Society 
of Nuclear Cardiology, Heart Rhythm Society, Society of 
Cardiovascular Anesthesiologists, Society for Cardiovascular 
Angiography and Interventions, Society for Vascular Medicine 
and Biology, and Society for Vascular Surgery. J Am Coll 
Cardiol 2007;50:e159-e241
78. Fleisher LA; American College of Cardiology/American Heart 
Association. Cardiac risk stratification for noncardiac surgery: 
update from the American College of Cardiology/American 
Heart Association 2007 guidelines. Cleve Clin J Med 2009;76 
Suppl 4:S9-S15
79. Freeman WK, Gibbons RJ. Perioperative cardiovascular 
assessment of patients undergoing noncardiac surgery. Mayo 
Clin Proc 2009;84:79-90
80. Holt NF. Perioperative cardiac risk reduction. Am Fam 
Physician 2012;85:239-246
81. Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, 
Hlatky MA. Relation of clinical and angiographic factors to 
functional capacity as measured by the Duke Activity Status 
Index. Am J Cardiol 1991;68:973-975
82. Fathala A, Hassan W. Role of multimodality cardiac imaging 
in preoperative cardiovascular evaluation before noncardiac 
surgery. Ann Card Anaesth 2011;14:134-145
83. Shah DJ, Kim HW, Kim RJ. Evaluation of ischemic heart 
disease. Heart Fail Clin 2009;5:315-332, v
84. Mavrogeni S, Papadopoulos G, Karanasios E, Cokkinos DV. 
How to image Kawasaki disease: a validation of different 
imaging techniques. Int J Cardiol 2008;124:27-31
85. Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis 
I, Baras P, et al. Magnetic resonance angiography is 
equivalent to X-ray coronary angiography for the evaluation 
of coronary arteries in Kawasaki disease. J Am Coll Cardiol 
2004;43:649-652
86. Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis 
I, Varlamis G, et al. Magnetic resonance angiography, 
function and viability evaluation in patients with Kawasaki 
disease. J Cardiovasc Magn Reson 2006;8:493-498
87. Greil GF, Stuber M, Botnar RM, Kissinger KV, Geva T, 
Newburger JW, et al. Coronary magnetic resonance 
angiography in adolescents and young adults with kawasaki 
disease. Circulation 2002;105:908-911
88. Greil GF, Seeger A, Miller S, Claussen CD, Hofbeck M, Botnar 
RM, et al. Coronary magnetic resonance angiography and 
vessel wall imaging in children with Kawasaki disease. 
Pediatr Radiol 2007;37:666-673
89. Ferket BS, Genders TS, Colkesen EB, Visser JJ, Spronk S, 
Steyerberg EW, et al. Systematic review of guidelines on 
imaging of asymptomatic coronary artery disease. J Am Coll 
Cardiol 2011;57:1591-1600
90. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd 
RM. Transmural extent of acute myocardial infarction predicts 
long-term improvement in contractile function. Circulation 
2001;104:1101-1107
91. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, 
et al. The use of contrast-enhanced magnetic resonance 
imaging to identify reversible myocardial dysfunction. N Engl 
J Med 2000;343:1445-1453
92. Romero J, Kahan J, Kelesidis I, Makani H, Wever-Pinzon 
O, Medina H, et al. CMR imaging for the evaluation of 
myocardial stunning after acute myocardial infarction: a 
meta-analysis of prospective trials. Eur Heart J Cardiovasc 
Imaging 2013;14:1080-1091
93. Chan RH, Leung AA, Manning WJ. Prognostic utility of 
late gadolinium enhancement cardiac magnetic resonance 
imaging in coronary artery disease: a meta-analysis. J 
Cardiovasc Magn Reson 2013;15 Suppl 1:O75
94. Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging 
assessing viability in patients with chronic ventricular 
dysfunction due to coronary artery disease: a meta-analysis 
of prospective trials. JACC Cardiovasc Imaging 2012;5:494-508
95. Trent RJ, Waiter GD, Hillis GS, McKiddie FI, Redpath 
TW, Walton S. Dobutamine magnetic resonance imaging 
as a predictor of myocardial functional recovery after 
revascularisation. Heart 2000;83:40-46
96. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, 
Petersen SE, Taggart DP, et al. Value of delayed-enhancement 
cardiovascular magnetic resonance imaging in predicting 
myocardial viability after surgical revascularization. 
Circulation 2004;110:1535-1541
97. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, 
Parker M, et al. Contrast-enhanced MRI and routine single 
photon emission computed tomography (SPECT) perfusion 
imaging for detection of subendocardial myocardial infarcts: 
an imaging study. Lancet 2003;361:374-379
98. Roes SD, Kaandorp TA, Marsan NA, Westenberg JJ, Dibbets-
Schneider P, Stokkel MP, et al. Agreement and disagreement 
683
Appropriate Use Criteria for CMR
Korean J Radiol 15(6), Nov/Dec 2014kjronline.org
between contrast-enhanced magnetic resonance imaging and 
nuclear imaging for assessment of myocardial viability. Eur J 
Nucl Med Mol Imaging 2009;36:594-601
99. Crean A, Khan SN, Davies LC, Coulden R, Dutka DP. 
Assessment of Myocardial Scar; Comparison Between F-FDG 
PET, CMR and Tc-Sestamibi. Clin Med Cardiol 2009;3:69-76
100. Heijenbrok-Kal MH, Fleischmann KE, Hunink MG. Stress 
echocardiography, stress single-photon-emission computed 
tomography and electron beam computed tomography for 
the assessment of coronary artery disease: a meta-analysis 
of diagnostic performance. Am Heart J 2007;154:415-423
101. Eitel I, Desch S, de Waha S, Fuernau G, Gutberlet M, Schuler 
G, et al. Long-term prognostic value of myocardial salvage 
assessed by cardiovascular magnetic resonance in acute 
reperfused myocardial infarction. Heart 2011;97:2038-2045
102. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, 
Schuler G, et al. Prognostic significance and determinants 
of myocardial salvage assessed by cardiovascular magnetic 
resonance in acute reperfused myocardial infarction. J Am 
Coll Cardiol 2010;55:2470-2479
103. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis 
JM, Neubauer S, et al. Troponin elevation after percutaneous 
coronary intervention directly represents the extent of 
irreversible myocardial injury: insights from cardiovascular 
magnetic resonance imaging. Circulation 2005;111:1027-1032
104. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm 
M, Dickstein K, et al. ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure 2012: The Task 
Force for the Diagnosis and Treatment of Acute and Chronic 
Heart Failure 2012 of the European Society of Cardiology. 
Developed in collaboration with the Heart Failure Association 
(HFA) of the ESC. Eur Heart J 2012;33:1787-1847
105. Fonseca C. Diagnosis of heart failure in primary care. Heart 
Fail Rev 2006;11:95-107
106. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, 
Mosterd A, Moons KG, et al. The diagnostic value of physical 
examination and additional testing in primary care patients 
with suspected heart failure. Circulation 2011;124:2865-2873
107. Assomull RG, Shakespeare C, Kalra PR, Lloyd G, Gulati A, 
Strange J, et al. Role of cardiovascular magnetic resonance 
as a gatekeeper to invasive coronary angiography in patients 
presenting with heart failure of unknown etiology. Circulation 
2011;124:1351-1360
108. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland 
JG, et al. Comparison of left ventricular ejection fraction and 
volumes in heart failure by echocardiography, radionuclide 
ventriculography and cardiovascular magnetic resonance; are 
they interchangeable? Eur Heart J 2000;21:1387-1396
109. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler 
MB, Hershberger RE, et al. Carvedilol produces dose-related 
improvements in left ventricular function and survival in 
subjects with chronic heart failure. MOCHA Investigators. 
Circulation 1996;94:2807-2816
110. Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, 
Caporotondi A, et al. Beta-blockade therapy in chronic 
heart failure: diastolic function and mitral regurgitation 
improvement by carvedilol. Am Heart J 2000;139:596-608
111. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-
Sendón J, Sharpe N; CAPRICORN Echo Substudy Investigators. 
Effects of carvedilol on left ventricular remodeling after 
acute myocardial infarction: the CAPRICORN Echo Substudy. 
Circulation 2004;109:201-206
112. Alfakih K, Reid S, Jones T, Sivananthan M. Assessment of 
ventricular function and mass by cardiac magnetic resonance 
imaging. Eur Radiol 2004;14:1813-1822
113. Holman ER, Buller VG, de Roos A, van der Geest RJ, Baur 
LH, van der Laarse A, et al. Detection and quantification of 
dysfunctional myocardium by magnetic resonance imaging. 
A new three-dimensional method for quantitative wall-
thickening analysis. Circulation 1997;95:924-931
114. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, 
Pennell DJ. Interstudy reproducibility of right ventricular 
volumes, function, and mass with cardiovascular magnetic 
resonance. Am Heart J 2004;147:218-223
115. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, 
Klein HU, et al. Comparison of interstudy reproducibility of 
cardiovascular magnetic resonance with two-dimensional 
echocardiography in normal subjects and in patients with 
heart failure or left ventricular hypertrophy. Am J Cardiol 
2002;90:29-34
116. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. 
Left ventricular volume measurement with echocardiography: 
a comparison of left ventricular opacification, three-
dimensional echocardiography, or both with magnetic 
resonance imaging. Eur Heart J 2009;30:98-106
117. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. 
Reduction in sample size for studies of remodeling in heart 
failure by the use of cardiovascular magnetic resonance. J 
Cardiovasc Magn Reson 2000;2:271-278
118. Kim YJ, Kim RJ. The role of cardiac MR in new-onset heart 
failure. Curr Cardiol Rep 2011;13:185-193
119. Valle-Muñoz A, Estornell-Erill J, Soriano-Navarro CJ, Nadal-
Barange M, Martinez-Alzamora N, Pomar-Domingo F, et al. 
Late gadolinium enhancement-cardiovascular magnetic 
resonance identifies coronary artery disease as the aetiology 
of left ventricular dysfunction in acute new-onset congestive 
heart failure. Eur J Echocardiogr 2009;10:968-974
120. Hamilton-Craig C, Strugnell WE, Raffel OC, Porto I, Walters 
DL, Slaughter RE. CT angiography with cardiac MRI: non-
invasive functional and anatomical assessment for the 
etiology in newly diagnosed heart failure. Int J Cardiovasc 
Imaging 2012;28:1111-1122
121. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke 
GL, et al. The relationship of left ventricular mass and 
geometry to incident cardiovascular events: the MESA (Multi-
Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 
2008;52:2148-2155
122. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo 
G, et al. Assessment and significance of left ventricular 
mass by cardiovascular magnetic resonance in hypertrophic 
cardiomyopathy. J Am Coll Cardiol 2008;52:559-566
123. Follath F, Cleland JG, Klein W, Murphy R. Etiology and 
684
Yoon et al.
Korean J Radiol 15(6), Nov/Dec 2014 kjronline.org
response to drug treatment in heart failure. J Am Coll Cardiol 
1998;32:1167-1172
124. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. 
Delayed enhancement cardiovascular magnetic resonance 
assessment of non-ischaemic cardiomyopathies. Eur Heart J 
2005;26:1461-1474
125. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott 
MD, Klocke FJ, et al. Myocardial scarring in asymptomatic 
or mildly symptomatic patients with hypertrophic 
cardiomyopathy. J Am Coll Cardiol 2002;40:2156-2164
126. Kim KH, Kim HK, Hwang IC, Lee SP, Park EA, Lee W, et al. 
Myocardial scarring on cardiovascular magnetic resonance in 
asymptomatic or minimally symptomatic patients with “pure” 
apical hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 
2012;14:52
127. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta 
A, Pennell DJ, et al. Gadolinium enhanced cardiovascular 
magnetic resonance in Anderson-Fabry disease. Evidence for 
a disease specific abnormality of the myocardial interstitium. 
Eur Heart J 2003;24:2151-2155
128. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding 
I, et al. Cardiovascular magnetic resonance in cardiac 
amyloidosis. Circulation 2005;111:186-193
129. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, 
Athanasiadis A, Vogelsberg H, et al. Cardiovascular 
magnetic resonance assessment of human myocarditis: a 
comparison to histology and molecular pathology. Circulation 
2004;109:1250-1258
130. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft 
FC, Dietz R. Contrast media-enhanced magnetic resonance 
imaging visualizes myocardial changes in the course of viral 
myocarditis. Circulation 1998;97:1802-1809
131. Klem I, Shah DJ, White RD, Pennell DJ, van Rossum AC, 
Regenfus M, et al. Prognostic value of routine cardiac 
magnetic resonance assessment of left ventricular ejection 
fraction and myocardial damage: an international, 
multicenter study. Circ Cardiovasc Imaging 2011;4:610-619
132. Klem I, Weinsaft JW, Bahnson TD, Hegland D, Kim HW, Hayes 
B, et al. Assessment of myocardial scarring improves risk 
stratification in patients evaluated for cardiac defibrillator 
implantation. J Am Coll Cardiol 2012;60:408-420
133. Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalani 
A, Dorian P, et al. Potential clinical impact of cardiovascular 
magnetic resonance assessment of ejection fraction on 
eligibility for cardioverter defibrillator implantation. J 
Cardiovasc Magn Reson 2012;14:69
134. Gao P, Yee R, Gula L, Krahn AD, Skanes A, Leong-Sit P, et 
al. Prediction of arrhythmic events in ischemic and dilated 
cardiomyopathy patients referred for implantable cardiac 
defibrillator: evaluation of multiple scar quantification 
measures for late gadolinium enhancement magnetic 
resonance imaging. Circ Cardiovasc Imaging 2012;5:448-456
135. Delgado V, van Bommel RJ, Bertini M, Borleffs CJ, Marsan 
NA, Arnold CT, et al. Relative merits of left ventricular 
dyssynchrony, left ventricular lead position, and myocardial 
scar to predict long-term survival of ischemic heart failure 
patients undergoing cardiac resynchronization therapy. 
Circulation 2011;123:70-78
136. Leyva F, Foley PW. Current and future role of cardiovascular 
magnetic resonance in cardiac resynchronization therapy. 
Heart Fail Rev 2011;16:251-262
137. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, 
et al. Cardiac resynchronization therapy guided by late 
gadolinium-enhancement cardiovascular magnetic resonance. 
J Cardiovasc Magn Reson 2011;13:29
138. Dickfeld T, Tian J, Ahmad G, Jimenez A, Turgeman A, Kuk 
R, et al. MRI-Guided ventricular tachycardia ablation: 
integration of late gadolinium-enhanced 3D scar in patients 
with implantable cardioverter-defibrillators. Circ Arrhythm 
Electrophysiol 2011;4:172-184
139. Junttila MJ, Fishman JE, Lopera GA, Pattany PM, Velazquez 
DL, Williams AR, et al. Safety of serial MRI in patients with 
implantable cardioverter defibrillators. Heart 2011;97:1852-
1856
140. Chessa M, Carrozza M, Butera G, Piazza L, Negura DG, 
Bussadori C, et al. Results and mid-long-term follow-up of 
stent implantation for native and recurrent coarctation of 
the aorta. Eur Heart J 2005;26:2728-2732
141. Hassan W, Awad M, Fawzy ME, Omrani AA, Malik S, Akhras 
N, et al. Long-term effects of balloon angioplasty on left 
ventricular hypertrophy in adolescent and adult patients 
with native coarctation of the aorta. Up to 18 years follow-
up results. Catheter Cardiovasc Interv 2007;70:881-886
142. Bogaert J, Kuzo R, Dymarkowski S, Janssen L, Celis I, Budts 
W, et al. Follow-up of patients with previous treatment 
for coarctation of the thoracic aorta: comparison between 
contrast-enhanced MR angiography and fast spin-echo MR 
imaging. Eur Radiol 2000;10:1847-1854
143. Geva T, Greil GF, Marshall AC, Landzberg M, Powell AJ. 
Gadolinium-enhanced 3-dimensional magnetic resonance 
angiography of pulmonary blood supply in patients with 
complex pulmonary stenosis or atresia: comparison with 
x-ray angiography. Circulation 2002;106:473-478
144. Prasad SK, Soukias N, Hornung T, Khan M, Pennell DJ, 
Gatzoulis MA, et al. Role of magnetic resonance angiography 
in the diagnosis of major aortopulmonary collateral 
arteries and partial anomalous pulmonary venous drainage. 
Circulation 2004;109:207-214
145. Fattori R, Bacchi Reggiani L, Pepe G, Napoli G, Bnà C, 
Celletti F, et al. Magnetic resonance imaging evaluation 
of aortic elastic properties as early expression of Marfan 
syndrome. J Cardiovasc Magn Reson 2000;2:251-256
146. Baumgartner D, Baumgartner C, Mátyás G, Steinmann B, 
Löffler-Ragg J, Schermer E, et al. Diagnostic power of aortic 
elastic properties in young patients with Marfan syndrome. J 
Thorac Cardiovasc Surg 2005;129:730-739
147. Geva T, Vick GW 3rd, Wendt RE, Rokey R. Role of spin echo 
and cine magnetic resonance imaging in presurgical planning 
of heterotaxy syndrome. Comparison with echocardiography 
and catheterization. Circulation 1994;90:348-356
148. Salehian O, Schwerzmann M, Merchant N, Webb GD, Siu SC, 
Therrien J. Assessment of systemic right ventricular function 
685
Appropriate Use Criteria for CMR
Korean J Radiol 15(6), Nov/Dec 2014kjronline.org
in patients with transposition of the great arteries using 
the myocardial performance index: comparison with cardiac 
magnetic resonance imaging. Circulation 2004;110:3229-3233
149. Warnes CA. Transposition of the great arteries. Circulation 
2006;114:2699-2709
150. Rutledge JM, Nihill MR, Fraser CD, Smith OE, McMahon 
CJ, Bezold LI. Outcome of 121 patients with congenitally 
corrected transposition of the great arteries. Pediatr Cardiol 
2002;23:137-145
151. Didier D, Higgins CB. Identification and localization of 
ventricular septal defect by gated magnetic resonance 
imaging. Am J Cardiol 1986;57:1363-1368
152. Hundley WG, Li HF, Lange RA, Pfeifer DP, Meshack BM, 
Willard JE, et al. Assessment of left-to-right intracardiac 
shunting by velocity-encoded, phase-difference magnetic 
resonance imaging. A comparison with oximetric and 
indicator dilution techniques. Circulation 1995;91:2955-2960
153. Körperich H, Gieseke J, Barth P, Hoogeveen R, Esdorn H, 
Peterschröder A, et al. Flow volume and shunt quantification 
in pediatric congenital heart disease by real-time magnetic 
resonance velocity mapping: a validation study. Circulation 
2004;109:1987-1993
154. Beerbaum P, Körperich H, Gieseke J, Barth P, Peuster 
M, Meyer H. Rapid left-to-right shunt quantification in 
children by phase-contrast magnetic resonance imaging 
combined with sensitivity encoding (SENSE). Circulation 
2003;108:1355-1361
155. American College of Cardiology; American Heart Association 
Task Force on Practice Guidelines (Writing Committee to 
revise the 1998 guidelines for the management of patients 
with valvular heart disease); Society of Cardiovascular 
Anesthesiologists, Bonow RO, Carabello BA, Chatterjee K, et 
al. ACC/AHA 2006 guidelines for the management of patients 
with valvular heart disease: a report of the American College 
of Cardiology/American Heart Association Task Force on 
Practice Guidelines (writing Committee to Revise the 1998 
guidelines for the management of patients with valvular 
heart disease) developed in collaboration with the Society of 
Cardiovascular Anesthesiologists endorsed by the Society for 
Cardiovascular Angiography and Interventions and the Society 
of Thoracic Surgeons. J Am Coll Cardiol 2006;48:e1-e148
156. Rebergen SA, Chin JG, Ottenkamp J, van der Wall EE, de 
Roos A. Pulmonary regurgitation in the late postoperative 
follow-up of tetralogy of Fallot. Volumetric quantitation by 
nuclear magnetic resonance velocity mapping. Circulation 
1993;88:2257-2266
157. Apitz C, Webb GD, Redington AN. Tetralogy of Fallot. Lancet 
2009;374:1462-1471
158. Therrien J, Provost Y, Merchant N, Williams W, Colman J, 
Webb G. Optimal timing for pulmonary valve replacement 
in adults after tetralogy of Fallot repair. Am J Cardiol 
2005;95:779-782
159. Oosterhof T, van Straten A, Vliegen HW, Meijboom FJ, van 
Dijk AP, Spijkerboer AM, et al. Preoperative thresholds for 
pulmonary valve replacement in patients with corrected 
tetralogy of Fallot using cardiovascular magnetic resonance. 
Circulation 2007;116:545-551
160. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, 
Davlouros PA, et al. Ventricular fibrosis suggested by 
cardiovascular magnetic resonance in adults with repaired 
tetralogy of fallot and its relationship to adverse markers of 
clinical outcome. Circulation 2006;113:405-413
161. Attenhofer Jost CH, Edmister WD, Julsrud PR, Dearani JA, 
Savas Tepe M, Warnes CA, et al. Prospective comparison of 
echocardiography versus cardiac magnetic resonance imaging 
in patients with Ebstein’s anomaly. Int J Cardiovasc Imaging 
2012;28:1147-1159
162. Yalonetsky S, Tobler D, Greutmann M, Crean AM, 
Wintersperger BJ, Nguyen ET, et al. Cardiac magnetic 
resonance imaging and the assessment of ebstein anomaly in 
adults. Am J Cardiol 2011;107:767-773 
163. Lemmer J, Heise G, Rentzsch A, Boettler P, Kuehne T, 
Dubowy KO, et al. Right ventricular function in grown-up 
patients after correction of congenital right heart disease. 
Clin Res Cardiol 2011;100:289-296
164. Grothoff M, Spors B, Abdul-Khaliq H, Gutberlet M. Evaluation 
of postoperative pulmonary regurgitation after surgical 
repair of tetralogy of Fallot: comparison between Doppler 
echocardiography and MR velocity mapping. Pediatr Radiol 
2008;38:186-191
165. Roest AA, Helbing WA, Kunz P, van den Aardweg JG, 
Lamb HJ, Vliegen HW, et al. Exercise MR imaging in the 
assessment of pulmonary regurgitation and biventricular 
function in patients after tetralogy of fallot repair. Radiology 
2002;223:204-211
166. Oosterhof T, Mulder BJ, Vliegen HW, de Roos A. 
Cardiovascular magnetic resonance in the follow-up of 
patients with corrected tetralogy of Fallot: a review. Am 
Heart J 2006;151:265-272
167. Oosterhof T, Mulder BJ, Vliegen HW, de Roos A. Corrected 
tetralogy of Fallot: delayed enhancement in right ventricular 
outflow tract. Radiology 2005;237:868-871
168. Davlouros PA, Kilner PJ, Hornung TS, Li W, Francis JM, Moon 
JC, et al. Right ventricular function in adults with repaired 
tetralogy of Fallot assessed with cardiovascular magnetic 
resonance imaging: detrimental role of right ventricular 
outflow aneurysms or akinesia and adverse right-to-left 
ventricular interaction. J Am Coll Cardiol 2002;40:2044-2052
169. Taylor AM, Dymarkowski S, Hamaekers P, Razavi R, Gewillig 
M, Mertens L, et al. MR coronary angiography and late-
enhancement myocardial MR in children who underwent 
arterial switch surgery for transposition of great arteries. 
Radiology 2005;234:542-547
170. Garg R, Powell AJ, Sena L, Marshall AC, Geva T. Effects of 
metallic implants on magnetic resonance imaging evaluation 
of Fontan palliation. Am J Cardiol 2005;95:688-691
171. Grosse-Wortmann L, Al-Otay A, Yoo SJ. Aortopulmonary 
collaterals after bidirectional cavopulmonary connection or 
Fontan completion: quantification with MRI. Circ Cardiovasc 
Imaging 2009;2:219-225
172. Fogel MA, Weinberg PM, Chin AJ, Fellows KE, Hoffman 
EA. Late ventricular geometry and performance changes 
686
Yoon et al.
Korean J Radiol 15(6), Nov/Dec 2014 kjronline.org
of functional single ventricle throughout staged Fontan 
reconstruction assessed by magnetic resonance imaging. J 
Am Coll Cardiol 1996;28:212-221
173. Cawley PJ, Maki JH, Otto CM. Cardiovascular magnetic 
resonance imaging for valvular heart disease: technique and 
validation. Circulation 2009;119:468-478
174. Søndergaard L, Hildebrandt P, Lindvig K, Thomsen C, 
Ståhlberg F, Kassis E, et al. Valve area and cardiac output 
in aortic stenosis: quantification by magnetic resonance 
velocity mapping. Am Heart J 1993;126:1156-1164
175. Caruthers SD, Lin SJ, Brown P, Watkins MP, Williams 
TA, Lehr KA, et al. Practical value of cardiac magnetic 
resonance imaging for clinical quantification of aortic valve 
stenosis: comparison with echocardiography. Circulation 
2003;108:2236-2243
176. Djavidani B, Debl K, Lenhart M, Seitz J, Paetzel C, Schmid 
FX, et al. Planimetry of mitral valve stenosis by magnetic 
resonance imaging. J Am Coll Cardiol 2005;45:2048-2053
177. Honda N, Machida K, Hashimoto M, Mamiya T, Takahashi T, 
Kamano T, et al. Aortic regurgitation: quantitation with MR 
imaging velocity mapping. Radiology 1993;186:189-194
178. Ley S, Eichhorn J, Ley-Zaporozhan J, Ulmer H, Schenk JP, 
Kauczor HU, et al. Evaluation of aortic regurgitation in 
congenital heart disease: value of MR imaging in comparison 
to echocardiography. Pediatr Radiol 2007;37:426-436
179. Kon MW, Myerson SG, Moat NE, Pennell DJ. Quantification of 
regurgitant fraction in mitral regurgitation by cardiovascular 
magnetic resonance: comparison of techniques. J Heart Valve 
Dis 2004;13:600-607
180. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell 
WE, Mitsumori L, et al. Prospective comparison of valve 
regurgitation quantitation by cardiac magnetic resonance 
imaging and transthoracic echocardiography. Circ Cardiovasc 
Imaging 2013;6:48-57
181. Lee C, Kim YM, Lee CH, Kwak JG, Park CS, Song JY, et al. 
Outcomes of pulmonary valve replacement in 170 patients 
with chronic pulmonary regurgitation after relief of right 
ventricular outflow tract obstruction: implications for 
optimal timing of pulmonary valve replacement. J Am Coll 
Cardiol 2012;60:1005-1014
182. Sarikouch S, Koerperich H, Dubowy KO, Boethig D, Boettler 
P, Mir TS, et al. Impact of gender and age on cardiovascular 
function late after repair of tetralogy of Fallot: percentiles 
based on cardiac magnetic resonance. Circ Cardiovasc 
Imaging 2011;4:703-711
183. Mercer-Rosa L, Yang W, Kutty S, Rychik J, Fogel M, 
Goldmuntz E. Quantifying pulmonary regurgitation and right 
ventricular function in surgically repaired tetralogy of Fallot: 
a comparative analysis of echocardiography and magnetic 
resonance imaging. Circ Cardiovasc Imaging 2012;5:637-643
184. Koca B, Öztunç F, Erog˘lu AG, Gökalp S, Dursun M, Yilmaz 
R. Evaluation of right ventricular function in patients with 
tetralogy of Fallot using the myocardial performance index 
and isovolumic acceleration: a comparison with cardiac 
magnetic resonance imaging. Cardiol Young 2014;24:422-429
185. Botnar R, Nagel E, Scheidegger MB, Pedersen EM, Hess 
O, Boesiger P. Assessment of prosthetic aortic valve 
performance by magnetic resonance velocity imaging. 
MAGMA 2000;10:18-26
186. Kozerke S, Hasenkam JM, Nygaard H, Paulsen PK, Pedersen 
EM, Boesiger P. Heart motion-adapted MR velocity mapping 
of blood velocity distribution downstream of aortic valve 
prostheses: initial experience. Radiology 2001;218:548-555
187. von Knobelsdorff-Brenkenhoff F, Rudolph A, Wassmuth R, 
Bohl S, Buschmann EE, Abdel-Aty H, et al. Feasibility of 
cardiovascular magnetic resonance to assess the orifice area 
of aortic bioprostheses. Circ Cardiovasc Imaging 2009;2:397-
404
188. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, 
Bluemke DA, et al. Diagnosis of arrhythmogenic right 
ventricular cardiomyopathy/dysplasia: proposed modification 
of the Task Force Criteria. Eur Heart J 2010;31:806-814
189. Sen-Chowdhry S, Prasad SK, Syrris P, Wage R, Ward D, 
Merrifield R, et al. Cardiovascular magnetic resonance in 
arrhythmogenic right ventricular cardiomyopathy revisited: 
comparison with task force criteria and genotype. J Am Coll 
Cardiol 2006;48:2132-2140
190. Keller DI, Osswald S, Bremerich J, Bongartz G, Cron TA, Hilti 
P, et al. Arrhythmogenic right ventricular cardiomyopathy: 
diagnostic and prognostic value of the cardiac MRI in 
relation to arrhythmia-free survival. Int J Cardiovasc Imaging 
2003;19:537-543; discussion 545-547
191. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, 
Nasir K, et al. Noninvasive detection of myocardial fibrosis 
in arrhythmogenic right ventricular cardiomyopathy using 
delayed-enhancement magnetic resonance imaging. J Am 
Coll Cardiol 2005;45:98-103
192. Hosch W, Kristen AV, Libicher M, Dengler TJ, Aulmann S, Heye 
T, et al. Late enhancement in cardiac amyloidosis: correlation 
of MRI enhancement pattern with histopathological findings. 
Amyloid 2008;15:196-204
193. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert 
EM, Greulich S, et al. Cardiovascular magnetic resonance 
in clinically suspected cardiac amyloidosis: noninvasive 
imaging compared to endomyocardial biopsy. J Am Coll 
Cardiol 2008;51:1022-1030
194. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards 
WD, et al. Role of cardiac magnetic resonance imaging in the 
detection of cardiac amyloidosis. JACC Cardiovasc Imaging 
2010;3:155-164
195. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi 
H, Fukui M, et al. Diagnosis of cardiac sarcoidosis and 
evaluation of the effects of steroid therapy by gadolinium-
DTPA-enhanced magnetic resonance imaging. Am J Med 
2001;110:520-527
196. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis 
S, Fang T, et al. The utility of cardiac biomarkers, tissue 
velocity and strain imaging, and cardiac magnetic resonance 
imaging in predicting early left ventricular dysfunction in 
patients with human epidermal growth factor receptor II-
positive breast cancer treated with adjuvant trastuzumab 
therapy. J Am Coll Cardiol 2011;57:2263-2270
687
Appropriate Use Criteria for CMR
Korean J Radiol 15(6), Nov/Dec 2014kjronline.org
197. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, 
Jenni R. Long-term follow-up of 34 adults with isolated left 
ventricular noncompaction: a distinct cardiomyopathy with 
poor prognosis. J Am Coll Cardiol 2000;36:493-500
198. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, 
Francis JM, Anderson RH, et al. Left ventricular non-
compaction: insights from cardiovascular magnetic resonance 
imaging. J Am Coll Cardiol 2005;46:101-105
199. Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg 
J, Longe TF, et al. Acute and reversible cardiomyopathy 
provoked by stress in women from the United States. 
Circulation 2005;111:472-479
200. Haghi D, Fluechter S, Suselbeck T, Kaden JJ, Borggrefe M, 
Papavassiliu T. Cardiovascular magnetic resonance findings in 
typical versus atypical forms of the acute apical ballooning 
syndrome (Takotsubo cardiomyopathy). Int J Cardiol 
2007;120:205-211
201. Mitchell JH, Hadden TB, Wilson JM, Achari A, Muthupillai 
R, Flamm SD. Clinical features and usefulness of cardiac 
magnetic resonance imaging in assessing myocardial viability 
and prognosis in Takotsubo cardiomyopathy (transient 
left ventricular apical ballooning syndrome). Am J Cardiol 
2007;100:296-301
202. Monney PA, Sekhri N, Burchell T, Knight C, Davies C, Deaner 
A, et al. Acute myocarditis presenting as acute coronary 
syndrome: role of early cardiac magnetic resonance in its 
diagnosis. Heart 2011;97:1312-1318
203. Jeserich M, Brunner E, Kandolf R, Olschewski M, Kimmel S, 
Friedrich MG, et al. Diagnosis of viral myocarditis by cardiac 
magnetic resonance and viral genome detection in peripheral 
blood. Int J Cardiovasc Imaging 2013;29:121-129
204. Marian AJ, Roberts R. The molecular genetic basis for 
hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-
670
205. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, 
Panse N, et al. Utility of cardiac magnetic resonance imaging 
in the diagnosis of hypertrophic cardiomyopathy. Circulation 
2005;112:855-861
206. Maron MS, Lesser JR, Maron BJ. Management implications 
of massive left ventricular hypertrophy in hypertrophic 
cardiomyopathy significantly underestimated by 
echocardiography but identified by cardiovascular magnetic 
resonance. Am J Cardiol 2010;105:1842-1843
207. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection 
of apical hypertrophic cardiomyopathy by cardiovascular 
magnetic resonance in patients with non-diagnostic 
echocardiography. Heart 2004;90:645-649
208. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, 
Olivotto I, et al. Hypertrophic cardiomyopathy phenotype 
revisited after 50 years with cardiovascular magnetic 
resonance. J Am Coll Cardiol 2009;54:220-228
209. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, 
Gibson CM, et al. Occurrence and frequency of arrhythmias 
in hypertrophic cardiomyopathy in relation to delayed 
enhancement on cardiovascular magnetic resonance. J Am 
Coll Cardiol 2008;51:1369-1374
210. Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, 
Haruki S, et al. Clinical implications of midventricular 
obstruction in patients with hypertrophic cardiomyopathy. J 
Am Coll Cardiol 2011;57:2346-2355
211. Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger 
KV, Udelson JE, et al. Right ventricular involvement in 
hypertrophic cardiomyopathy. Am J Cardiol 2007;100:1293-
1298
212. Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz 
R, et al. Noninvasive detection of fibrosis applying contrast-
enhanced cardiac magnetic resonance in different forms of 
left ventricular hypertrophy relation to remodeling. J Am Coll 
Cardiol 2009;53:284-291
213. Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, 
Ralph-Edwards A, et al. Myocardial fibrosis in hypertrophic 
cardiomyopathy: accurate reflection of histopathological 
findings by CMR. JACC Cardiovasc Imaging 2013;6:587-596
214. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti 
C, et al. Evaluation of techniques for the quantification of 
myocardial scar of differing etiology using cardiac magnetic 
resonance. JACC Cardiovasc Imaging 2011;4:150-156
215. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, 
et al. The histologic basis of late gadolinium enhancement 
cardiovascular magnetic resonance in hypertrophic 
cardiomyopathy. J Am Coll Cardiol 2004;43:2260-2264
216. O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage 
R, et al. Prognostic significance of myocardial fibrosis in 
hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-
874
217. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert 
EM, et al. Myocardial scar visualized by cardiovascular 
magnetic resonance imaging predicts major adverse events 
in patients with hypertrophic cardiomyopathy. J Am Coll 
Cardiol 2010;56:875-887
218. Ismail TF, Prasad SK, Pennell DJ. Prognostic importance 
of late gadolinium enhancement cardiovascular magnetic 
resonance in cardiomyopathy. Heart 2012;98:438-442
219. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, 
Hanna C, et al. Clinical profile and significance of delayed 
enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 
2008;1:184-191
220. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman 
MJ, Sorajja P, et al. Characteristics and clinical significance 
of late gadolinium enhancement by contrast-enhanced 
magnetic resonance imaging in patients with hypertrophic 
cardiomyopathy. Circ Heart Fail 2010;3:51-58
221. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic 
value of late gadolinium enhancement in clinical outcomes 
for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 
2012;5:370-377
222. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, 
Pennell DJ. Toward clinical risk assessment in hypertrophic 
cardiomyopathy with gadolinium cardiovascular magnetic 
resonance. J Am Coll Cardiol 2003;41:1561-1567
223. Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, 
Haghi D, et al. Extent of late gadolinium enhancement 
688
Yoon et al.
Korean J Radiol 15(6), Nov/Dec 2014 kjronline.org
detected by cardiovascular magnetic resonance correlates 
with the inducibility of ventricular tachyarrhythmia in 
hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 
2010;12:30
224. To AC, Dhillon A, Desai MY. Cardiac magnetic resonance 
in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 
2011;4:1123-1137
225. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto 
YM, et al. Structural abnormalities of the inferoseptal left 
ventricular wall detected by cardiac magnetic resonance 
imaging in carriers of hypertrophic cardiomyopathy 
mutations. J Am Coll Cardiol 2006;48:2518-2523
226. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson 
CM, et al. Prevalence and clinical profile of myocardial crypts 
in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 
2012;5:441-447
227. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson 
CM, Lesser JR, et al. Mitral valve abnormalities identified 
by cardiovascular magnetic resonance represent a primary 
phenotypic expression of hypertrophic cardiomyopathy. 
Circulation 2011;124:40-47
228. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late 
gadolinium enhancement in genotype positive-phenotype 
negative hypertrophic cardiomyopathy. JACC Cardiovasc 
Imaging 2012;5:119-122
229. Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, 
Van Assche L, et al. LV thrombus detection by routine 
echocardiography: insights into performance characteristics 
using delayed enhancement CMR. JACC Cardiovasc Imaging 
2011;4:702-712
230. Mollet NR, Dymarkowski S, Volders W, Wathiong J, Herbots L, 
Rademakers FE, et al. Visualization of ventricular thrombi with 
contrast-enhanced magnetic resonance imaging in patients 
with ischemic heart disease. Circulation 2002;106:2873-2876
231. Hong YJ, Hur J, Kim YJ, Lee HJ, Nam JE, Kim HY, et al. The 
usefulness of delayed contrast-enhanced cardiovascular 
magnetic resonance imaging in differentiating cardiac 
tumors from thrombi in stroke patients. Int J Cardiovasc 
Imaging 2011;27 Suppl 1:89-95
232. Weinsaft JW, Kim RJ, Ross M, Krauser D, Manoushagian S, 
LaBounty TM, et al. Contrast-enhanced anatomic imaging 
as compared to contrast-enhanced tissue characterization 
for detection of left ventricular thrombus. JACC Cardiovasc 
Imaging 2009;2:969-979
233. Motwani M, Kidambi A, Herzog BA, Uddin A, Greenwood JP, 
Plein S. MR imaging of cardiac tumors and masses: a review of 
methods and clinical applications. Radiology 2013;268:26-43
234. Fieno DS, Saouaf R, Thomson LE, Abidov A, Friedman JD, 
Berman DS. Cardiovascular magnetic resonance of primary 
tumors of the heart: a review. J Cardiovasc Magn Reson 
2006;8:839-853
235. Gulati G, Sharma S, Kothari SS, Juneja R, Saxena A, 
Talwar KK. Comparison of echo and MRI in the imaging 
evaluation of intracardiac masses. Cardiovasc Intervent Radiol 
2004;27:459-469
236. Francone M, Dymarkowski S, Kalantzi M, Rademakers FE, 
Bogaert J. Assessment of ventricular coupling with real-
time cine MRI and its value to differentiate constrictive 
pericarditis from restrictive cardiomyopathy. Eur Radiol 
2006;16:944-951
237. Mastouri R, Sawada SG, Mahenthiran J. Noninvasive imaging 
techniques of constrictive pericarditis. Expert Rev Cardiovasc 
Ther 2010;8:1335-1347
238. Zurick AO, Bolen MA, Kwon DH, Tan CD, Popovic ZB, 
Rajeswaran J, et al. Pericardial delayed hyperenhancement 
with CMR imaging in patients with constrictive pericarditis 
undergoing surgical pericardiectomy: a case series with 
histopathological correlation. JACC Cardiovasc Imaging 
2011;4:1180-1191
239. Axel L. Assessment of pericardial disease by magnetic 
resonance and computed tomography. J Magn Reson Imaging 
2004;19:816-826
240. Shiga T, Wajima Z, Apfel CC, Inoue T, Ohe Y. Diagnostic 
accuracy of transesophageal echocardiography, helical 
computed tomography, and magnetic resonance imaging for 
suspected thoracic aortic dissection: systematic review and 
meta-analysis. Arch Intern Med 2006;166:1350-1356
241. Lacomis JM, Pealer K, Fuhrman CR, Barley D, Wigginton W, 
Schwartzman D. Direct comparison of computed tomography 
and magnetic resonance imaging for characterization of 
posterior left atrial morphology. J Interv Card Electrophysiol 
2006;16:7-13
242. Kato R, Lickfett L, Meininger G, Dickfeld T, Wu R, Juang G, et 
al. Pulmonary vein anatomy in patients undergoing catheter 
ablation of atrial fibrillation: lessons learned by use of 
magnetic resonance imaging. Circulation 2003;107:2004-2010
243. Mansour M, Refaat M, Heist EK, Mela T, Cury R, Holmvang 
G, et al. Three-dimensional anatomy of the left atrium by 
magnetic resonance angiography: implications for catheter 
ablation for atrial fibrillation. J Cardiovasc Electrophysiol 
2006;17:719-723
244. Durongpisitkul K, Tang NL, Soongswang J, Laohaprasitiporn 
D, Nana A, Kangkagate C. Cardiac magnetic resonance 
imaging of atrial septal defect for transcatheter closure. J 
Med Assoc Thai 2002;85 Suppl 2:S658-S666
245. Weber C, Weber M, Ekinci O, Neumann T, Deetjen A, Rolf A, 
et al. Atrial septal defects type II: noninvasive evaluation 
of patients before implantation of an Amplatzer Septal 
Occluder and on follow-up by magnetic resonance imaging 
compared with TEE and invasive measurement. Eur Radiol 
2008;18:2406-2413
246. Thomson LE, Crowley AL, Heitner JF, Cawley PJ, Weinsaft JW, 
Kim HW, et al. Direct en face imaging of secundum atrial 
septal defects by velocity-encoded cardiovascular magnetic 
resonance in patients evaluated for possible transcatheter 
closure. Circ Cardiovasc Imaging 2008;1:31-40
247. La Manna A, Sanfilippo A, Capodanno D, Salemi A, Polizzi 
G, Deste W, et al. Cardiovascular magnetic resonance for 
the assessment of patients undergoing transcatheter aortic 
valve implantation: a pilot study. J Cardiovasc Magn Reson 
2011;13:82
